U.S. patent application number 11/471857 was filed with the patent office on 2006-10-19 for p. aeruginosa mucoid exopolysaccharide specific binding peptides.
This patent application is currently assigned to The Brigham and Women's Hospital, Inc.. Invention is credited to Lisa Cavacini, Gerald B. Pier, Marshall Posner, Michael J. Preston.
Application Number | 20060235206 11/471857 |
Document ID | / |
Family ID | 35785628 |
Filed Date | 2006-10-19 |
United States Patent
Application |
20060235206 |
Kind Code |
A1 |
Pier; Gerald B. ; et
al. |
October 19, 2006 |
P. aeruginosa mucoid exopolysaccharide specific binding
peptides
Abstract
The present invention relates to peptides, particularly human
monoclonal antibodies, that bind specifically to P. aeruginosa
mucoid exopolysaccharide. The invention further provides methods
for using these peptides in the diagnosis, prophylaxis and therapy
of P. aeruginosa infection and related disorders (e.g., cystic
fibrosis). Some antibodies of the invention enhance
opsonophagocytic killing of multiple mucoid strains of P.
aeruginosa. Compositions of these peptides, including
pharmaceutical compositions, are also provided, as are functionally
equivalent variants of such peptides.
Inventors: |
Pier; Gerald B.; (Brookline,
MA) ; Preston; Michael J.; (Alna, ME) ;
Cavacini; Lisa; (Natick, MA) ; Posner; Marshall;
(Medfield, MA) |
Correspondence
Address: |
WOLF GREENFIELD & SACKS, PC
FEDERAL RESERVE PLAZA
600 ATLANTIC AVENUE
BOSTON
MA
02210-2206
US
|
Assignee: |
The Brigham and Women's Hospital,
Inc.
Boston
MA
Beth Israel Deaconess Medical Center, Inc.
Boston
MA
|
Family ID: |
35785628 |
Appl. No.: |
11/471857 |
Filed: |
June 21, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10440522 |
May 16, 2003 |
|
|
|
11471857 |
Jun 21, 2006 |
|
|
|
10153437 |
May 21, 2002 |
6962813 |
|
|
10440522 |
May 16, 2003 |
|
|
|
60292365 |
May 21, 2001 |
|
|
|
Current U.S.
Class: |
530/387.1 ;
530/388.4 |
Current CPC
Class: |
A61K 39/00 20130101;
A61K 2039/505 20130101; A61P 13/12 20180101; A61P 17/00 20180101;
C07K 16/1214 20130101; A61P 27/02 20180101; A61P 43/00 20180101;
A61P 25/02 20180101; A61P 31/04 20180101; A61P 1/16 20180101; A61P
11/00 20180101; C07K 2317/565 20130101; A61P 27/16 20180101; A61P
21/00 20180101; C07K 2317/56 20130101; A61P 13/10 20180101 |
Class at
Publication: |
530/387.1 ;
530/388.4 |
International
Class: |
C07K 16/12 20060101
C07K016/12 |
Goverment Interests
GOVERNMENT SUPPORT
[0002] This work was funded in part by grant number HL-58346, from
the National Institutes of Health. Accordingly, the United States
Government may have certain rights to this invention.
Claims
1-74. (canceled)
75. A composition comprising an isolated antibody or antibody
fragment that selectively binds to P. aeruginosa mucoid
exopolysaccharide (MEP) and comprises at least two MEP-binding CDR
amino acid sequences.
76. The composition of claim 75, wherein the at least two
MEP-binding CDR amino acid sequences comprise one or two CDR3 amino
acid sequences.
77. The composition of claim 76, wherein the one or two CDR3 amino
acid sequences are selected from the group consisting of SEQ ID
NO:23, SEQ ID NO:26, SEQ ID NO:29 and SEQ ID NO:32.
78. The composition of claim 75, wherein the at least two
MEP-binding CDR amino acid sequences comprise one or two CDR2 amino
acid sequences.
79. The composition of claim 78, wherein the one or two CDR2 amino
acid sequence are selected from the group consisting of SEQ ID
NO:22, SEQ ID NO:25, SEQ ID NO:28 and SEQ ID NO:31.
80. The composition of claim 75, wherein the isolated antibody or
antibody fragment comprises at least three MEP-binding CDR amino
acid sequences.
81. The composition of claim 80, wherein the at least three
MEP-binding CDR amino acid sequences comprise a CDR3 amino acid
sequence, a CDR2 amino acid sequence and a CDR1 amino acid
sequence.
82. The composition of claim 81, wherein the at least three
MEP-binding CDR amino acid sequences comprise (a) SEQ ID NOs: 21,
22 and 23; or (b) SEQ ID NOs: 30, 31 and 32.
83. The composition of claim 75, wherein the isolated antibody or
antibody fragment is a human antibody or antibody fragment.
84. The composition of claim 75, wherein the isolated antibody or
antibody fragment is a human monoclonal antibody or antibody
fragment.
85. The composition of claim 75, further comprising a
pharmaceutically acceptable carrier.
86. The composition of claim 75, wherein the isolated antibody or
antibody fragment is labeled with a detectable label.
87. The composition of claim 75, wherein the isolated antibody or
antibody fragment is an isolated monoclonal antibody fragment
selected from the group consisting of an F(ab').sub.2 fragment, an
Fd fragment, an Fv fragment, and an Fab fragment.
88. The composition of claim 75, wherein the isolated antibody or
antibody fragment enhances opsonophagocytosis of P. aeruginosa.
89. A method for detecting P. aeruginosa in a subject comprising
determining a test level of binding of the isolated antibody or
antibody fragment of claim 75 to a sample in or from a subject, and
comparing the test level of binding to a control, wherein a test
level of binding that is greater than the control is indicative of
the presence of P. aeruginosa in the sample.
90. A method for treating a subject having, or at risk of
developing, a P. aeruginosa infection or a P. aeruginosa related
disorder comprising administering to a subject in need of such
treatment the isolated antibody or antibody fragment of claim 75 in
an amount effective to inhibit a P. aeruginosa infection or the
disorder.
Description
RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S.
non-provisional application filed May 21, 2002, entitled "P.
AERUGINOSA MUCOID EXOPOLYSACCHARIDE SPECIFIC BINDING PEPTIDES",
having Ser. No. 10/153,437, which claims priority to U.S.
Provisional Patent Application filed May 21, 2001, entitled "P.
AERUGINOSA MUCOID EXOPOLYSACCHARIDE SPECIFIC BINDING PEPTIDES",
having Ser. No. 60/292,365, the contents of which are incorporated
by reference herein in their entirety.
FIELD OF THE INVENTION
[0003] This invention relates generally to prevention and treatment
of Pseudomonas aeruginosa (P. aeruginosa) infections and related
disorders (e.g., cystic fibrosis) using peptides, including human
monoclonal antibodies, that bind to mucoid exopolysaccharide (MEP)
of P. aeruginosa.
BACKGROUND OF THE INVENTION
[0004] P. aeruginosa is an opportunistic organism capable of
colonizing skin, ear, lung and bowel. In healthy individuals, such
colonization does not normally cause a problem. However, if the
individual also has an underlying disorder or condition that
compromises their immunity, then infection can be serious. Examples
of such disorders or conditions include chemotherapy-induced
immunosuppression, diabetes mellitus, cancer, AIDS and cystic
fibrosis. It has been estimated that more than 70% of patients with
cystic fibrosis are infected with P. aeruginosa. In these patients,
P. aeruginosa infection is associated with chronic obstructive
bronchitis.
[0005] Colonization of P. aeruginosa begins with attachment of the
bacterium to epithelial tissues (e.g., lung epithelia). Mucoid
strains of P. aeruginosa produce a mucoid exopolysaccharide (i.e.,
MEP or alginate) which is used by the bacterium throughout the
infection. MEP is a polymer of uronic acids.
[0006] The bacterium can be relatively resistant to antibiotic
therapy and innate and adaptive immune mechanisms, including
antibody and complement mediated pathways. MEP is believed to be a
contributing factor to immune resistance of the microbe.
SUMMARY OF THE INVENTION
[0007] The present invention relates generally to the
identification and use of peptides that bind to P. aeruginosa
mucoid exopolysaccharide (MEP). Peptides utilizing the variable
region sequences described herein include polypeptides, monoclonal
antibodies (such as human monoclonal antibodies), and antibody
fragments. A common feature of the peptides disclosed herein is
their ability to recognize and bind to P. aeruginosa MEP
specifically. An important characteristic of some of the antibodies
and antibody fragments provided by the invention is their ability
to enhance opsonization and phagocytosis (i.e., opsonophagocytosis)
of P. aeruginosa.
[0008] In one aspect, the invention provides a composition that
comprises an isolated peptide or a functionally equivalent variant
thereof that binds, preferably selectively, to P. aeruginosa MEP
and which comprises an amino acid sequence of a P. aeruginosa
MEP-binding complementarity determining region (CDR). The P.
aeruginosa MEP-binding CDR may be selected from the group of heavy
and light chain CDRs derived from the antibodies of the invention.
Each heavy and light chain possesses three separate CDRs, namely
CDR1, CDR2 and CDR3. Thus, the P. aeruginosa MEP-binding CDR may be
a P. aeruginosa MEP-binding CDR3, or a P. aeruginosa MEP-binding
CDR2, or a P. aeruginosa MEP-binding CDR1. These CDRs comprise
amino acid sequences selected from the group consisting of SEQ ID
NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ
ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30,
SEQ ID NO:31 and SEQ ID NO:32.
[0009] SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:30, SEQ
ID NO:31 and SEQ ID NO:32 are amino acid sequences of CDRs derived
from P. aeruginosa MEP-binding heavy chain variable regions
disclosed herein. SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID
NO:27, SEQ ID NO:28 and SEQ ID NO:29 are amino acid sequences of
CDRs derived from P. aeruginosa MEP-binding light chain variable
regions disclosed herein.
[0010] The invention embraces a number of different embodiments
relating to the foregoing isolated peptides. The isolated peptides
preferably comprise a P. aeruginosa MEP-binding CDR. In one
embodiment, the P. aeruginosa MEP-binding CDR is a P. aeruginosa
MEP-binding CDR3. The CDR3 may be a light chain CDR3 or a heavy
chain CDR3. Such CDR3 amino acid sequences are selected from the
group consisting of SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:29 and
SEQ ID NO:32. Amino acid sequences of heavy chain CDR3 include SEQ
ID NO:23 and SEQ ID NO:32. Amino acid sequences of light chain CDR3
include SEQ ID NO:26 and SEQ ID NO:29. In another embodiment, the
isolated peptide comprises an amino acid sequence of a light chain
CDR3 and an amino acid sequence of a heavy chain CDR3.
[0011] In another embodiment, the P. aeruginosa MEP-binding CDR is
a P. aeruginosa MEP-binding CDR2. The CDR2 may be a light chain
CDR2 or a heavy chain CDR2. Such CDR2 amino acid sequences are
selected from the group consisting of SEQ ID NO:22, SEQ ID NO:25,
SEQ ID NO:28 and SEQ ID NO:3 1. Amino acid sequences of heavy chain
CDR2 include SEQ ID NO:22 and SEQ ID NO:31. Amino acid sequences of
light chain CDR2 include SEQ ID NO:25 and SEQ ID NO:28. In another
embodiment, the isolated peptide comprises an amino acid sequence
of a light chain CDR2 and an amino acid sequence of a heavy chain
CDR2.
[0012] In yet another embodiment, the P. aeruginosa MEP-binding CDR
is a P. aeruginosa MEP-binding CDR1. The CDR1 may be a light chain
CDR1 or a heavy chain CDR1. Such CDR1 amino acid sequences are
selected from the group consisting of SEQ ID NO:21, SEQ ID NO:24,
SEQ ID NO:27 and SEQ ID NO:30. Amino acid sequences of heavy chain
CDR1 include SEQ ID NO:21 and SEQ ID NO:30. Amino acid sequences of
light chain CDR1 include SEQ ID NO:24 and SEQ ID NO:27. In another
embodiment, the isolated peptide comprises an amino acid sequence
of a light chain CDR1 and an amino acid sequence of a heavy chain
CDR1.
[0013] The invention also intends to embrace isolated peptides
which comprise any combination of the disclosed amino acid
sequences of heavy and light chain CDR1, CDR2 and CDR3, provided
the isolated peptide binds to P. aeruginosa MEP. In important
embodiments, the isolated peptide binds selectively to P.
aeruginosa MEP.
[0014] In one embodiment, the isolated peptide comprises an amino
acid sequence of a heavy or light chain variable region of an
antibody disclosed herein. In important embodiments, the amino acid
sequences are selected from the group consisting of SEQ ID NO:5,
SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8. SEQ ID NO:5 and SEQ ID
NO:8 are amino acid sequences of heavy chain variable regions of
the P. aeruginosa MEP-binding antibodies disclosed herein. SEQ ID
NO:6 and SEQ ID NO:7 are amino acid sequences of light chain
variable regions of the P. aeruginosa MEP-binding antibodies
disclosed herein. These heavy and light chain variable region
sequences contain sequence of both framework and CDRs, as described
in the Examples.
[0015] In one embodiment, the isolated peptide comprises an amino
acid sequence of a CDR derived from a MEP-binding heavy chain
variable region and an amino acid sequence of a CDR derived from a
MEP-binding light chain variable region.
[0016] In one embodiment, the isolated peptide is an isolated
antibody or antibody fragment. The isolated antibody or antibody
fragment may be an isolated intact soluble monoclonal antibody. The
isolated antibody or antibody fragment may be an isolated
monoclonal antibody fragment selected from the group consisting of
an F(ab').sub.2 fragment, an Fd fragment, and an Fab fragment. In
preferred embodiments, the isolated antibody or antibody fragment
enhances opsonophagocytosis of P. aeruginosa. Such an antibody or
antibody fragment is referred to herein as "an opsonic antibody or
antibody fragment". In an important embodiment, the isolated
antibody or antibody fragment comprises an Fc domain in addition to
comprising one or more P. aeruginosa MEP-binding CDR. Accordingly,
in some embodiments, the isolated antibody or antibody fragment
comprises one or more P. aeruginosa MEP-binding CDR and enhances
opsonophagocytosis of P. aeruginosa.
[0017] In some embodiments, particularly those in which the
isolated peptide is an antibody or an antibody fragment, the
peptide comprises two amino acid sequences selected from the group
consisting of heavy and light chain variable region amino acid
sequences, i.e., SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID
NO:8. In some preferred embodiments, the isolated antibody or
antibody fragment comprises one heavy chain variable region amino
acid sequence selected from the group consisting of SEQ ID NO:5 and
SEQ ID NO:8, and one light chain variable region amino acid
sequence selected from the group consisting of SEQ ID NO:6 and SEQ
ID NO:7. In certain embodiments, the isolated antibody or antibody
fragment comprises a heavy chain variable region having an amino
acid sequence of SEQ ID NO:5 and a light chain variable region
having an amino acid sequence of SEQ ID NO:6. In other embodiments,
the isolated antibody or antibody fragment comprises a heavy chain
variable region having an amino acid sequence of SEQ ID NO:5 and a
light chain variable region having an amino acid sequence of SEQ ID
NO:7. In still other embodiments, the isolated antibody or antibody
fragment comprises a heavy chain variable region having an amino
acid sequence of SEQ ID NO:8 and a light chain variable region
having an amino acid sequence of SEQ ID NO:6. And in still further
embodiments, the isolated antibody or antibody fragment comprises a
heavy chain variable region having an amino acid sequence of SEQ ID
NO:8 and a light chain variable region having an amino acid
sequence of SEQ ID NO:7. The antibody and antibody fragments of the
invention similarly may comprise one or more of the P. aeruginosa
MEP-binding CDRs disclosed herein, or functionally equivalent
variants thereof.
[0018] The peptides of the invention, including antibodies and
antibody fragments, have particular utility in the detection of P.
aeruginosa bacteria, the diagnosis of P. aeruginosa infection and
the prevention and treatment of such infections and the disorders
with which they are associated.
[0019] Accordingly, in another aspect, the invention provides a
method for detecting P. aeruginosa in a subject. The method
involves determining a level of binding of an isolated peptide or a
functionally equivalent variant thereof to a sample in or from a
subject (i.e., a test level of binding), and comparing the test
level of binding to a control. The isolated peptide selectively
binds to P. aeruginosa MEP (i.e., a MEP-binding peptide) and
comprises a P. aeruginosa MEP-binding CDR, or a functionally
equivalent variant thereof. The P. aeruginosa MEP-binding CDR may
be selected from the group consisting of light chain or heavy chain
CDRs, as described above. A test level of binding that is greater
than the control is indicative of P. aeruginosa in the sample, and
thus in the subject. The control is the level of binding of the
peptide to a control sample in or from a subject that is known to
be negative for P. aeruginosa. In one embodiment, the test level of
binding is measured in vitro, and involves the harvest of a sample
from the subject. Alternatively, the test level of binding is
measured in vivo, and involves administering the isolated peptide
to the subject, preferably in a pharmaceutical composition as
described herein. Even more preferably, the peptide is conjugated
to a detectable label or a label capable of being detected (e.g.,
biotin or avidin). In one embodiment, the subject is at risk of
developing a P. aeruginosa infection. In another embodiment, the
subject has cystic fibrosis. The peptide may be an antibody or
antibody fragment, which may in turn enhance opsonophagocytosis,
but it is not so limited.
[0020] In yet a further aspect, the invention provides a method for
treating a subject having, or at risk of developing, a P.
aeruginosa infection. The method involves administering to a
subject in need of such treatment an isolated peptide or a
functionally equivalent variant thereof that binds, preferably
selectively, to P. aeruginosa MEP, and comprises a P. aeruginosa
MEP-binding CDR. The CDR comprises an amino acid sequence of a
light chain or heavy chain CDR of the antibodies of the invention,
as described above. The isolated peptide is administered to the
subject in an amount effective to inhibit a P. aeruginosa
infection. In one embodiment, the subject has cystic fibrosis. In
an important embodiment, the isolated peptide is an isolated
antibody or antibody fragment. In a preferred embodiment, the
isolated antibody or antibody fragment is capable of
opsonophagocytosis of P. aeruginosa. In some embodiments, more than
one such peptide is administered to a subject.
[0021] In another aspect of the invention, the isolated peptide can
be used in the delivery of, for example, imaging or cytotoxic
agents to P. aeruginosa colonies or individual bacteria in vivo. In
some embodiments, the peptides can be conjugated to agents such as
but not limited to antibiotics. In other embodiments, the peptide
may be conjugated to a cytotoxic agent (e.g., a bactericide)
allowing the agent to be delivered to a P. aeruginosa bacterium or
bacterial colony upon in vivo administration of the peptide.
[0022] In a related aspect, the invention provides a method for
treating a subject having, or at risk of developing, a P.
aeruginosa related disorder (i.e., a disorder related to or
associated with a P. aeruginosa infection). The method involves
administering to a subject in need of such treatment an isolated
peptide of the invention, or a functionally equivalent variant
thereof, in an effective amount to inhibit the P. aeruginosa
related disorder. A P. aeruginosa related disorder may be selected
from the group of disorders consisting of cystic fibrosis,
ulcerative keratitis, pneumonia, bacteremia, organ infection such
as kidney, bladder, liver, brain, skin, muscle, lymph node or sinus
infection. In an important embodiment, the isolated peptide is an
isolated antibody or antibody fragment. In a preferred embodiment,
the isolated antibody or antibody fragment is capable of
opsonophagocytosis of P. aeruginosa.
[0023] In certain embodiments of the treatment methods provided
herein, the isolated peptide is co-administered with another
therapeutic agent. The therapeutic agent may be one that is used
prophylactically or therapeutically in a P. aeruginosa infection,
such as for example an antibiotic. Alternatively, it may be an
agent that is used in the treatment of a P. aeruginosa related
disorder, such as for example N-acetyl cysteine or DNase which are
used in the treatment of cystic fibrosis. When administered in
conjunction with an antibiotic, the isolated peptide can enhance
the cytocidal effect of the antibiotic by facilitating entry of the
antibiotic into a P. aeruginosa colony. This is especially the case
where the peptide is an antibody or an antibody fragment that
enhances opsonophagocytosis. In some embodiments, the treatment
methods involve administering synergistic amounts of the isolated
peptide and the other therapeutic agent.
[0024] In yet another aspect, the invention provides pharmaceutical
compositions that comprise one or more of the foregoing isolated
peptides, such as one or more of the foregoing isolated antibodies
or antibody fragments, or a functionally equivalent variant,
thereof and a pharmaceutically acceptable carrier. In one
embodiment, the pharmaceutical composition comprises a peptide that
is an isolated antibody or antibody fragment that binds to P.
aeruginosa MEP, and enhances opsonophagocytosis of P. aeruginosa.
The isolated peptide may be conjugated to a number of compounds
including but not limited to detectable labels and cytotoxic
agents. In some important embodiments, the isolated peptide is
present in a prophylactically or therapeutically effective amount.
In another embodiment, the isolated peptide is present in an
effective amount for detecting P. aeruginosa in a sample in or from
a subject. In a related aspect, the invention provides a method for
manufacturing a medicament comprising contacting an isolated
peptide of the invention with a pharmaceutically acceptable
carrier.
[0025] In a further aspect, the invention provides an isolated
nucleic acid molecule comprising a nucleotide sequence that codes
for a P. aeruginosa MEP-binding CDR. The CDR may be a CDR1, CDR2 or
CDR3 from the heavy or light chains of the antibodies of the
invention. In one embodiment, the isolated nucleic acid molecule
comprises a nucleotide sequence selected from the group consisting
of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID
NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ
ID NO:18, SEQ ID NO:19 and SEQ ID NO:20. SEQ ID NO:9, SEQ ID NO:10,
SEQ ID NO:11, SEQ ID NO:18, SEQ ID NO:19 and SEQ ID NO:20 are
nucleotide sequences of heavy chain CDR. SEQ ID NO:12, SEQ ID
NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16 and SEQ ID NO:17
are nucleotide sequences of light chain CDR. In another embodiment,
the isolated nucleic acid molecule comprises a nucleotide sequence
selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ
ID NO:3, and SEQ ID NO:4. Isolated nucleic acid molecules
comprising a nucleotide sequence that encodes a P. aeruginosa
MEP-binding peptide having an amino acid sequence selected from the
group consisting of SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ
ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28,
SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32, and in a
separate embodiment SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ
ID NO:8, are also embraced by the invention.
[0026] In related aspects, the invention provides an expression
vector comprising the foregoing isolated nucleic acid molecules
operably linked to a promoter, host cells transformed or
transfected with such expression vectors, and isolated peptides
encoded by the isolated nucleic acid molecules.
[0027] The invention is yet another aspect provides cell lines that
produce the antibodies described herein.
[0028] These and other embodiments of the invention will be
described in greater detail herein.
BRIEF DESCRIPTION OF THE FIGURES
[0029] FIG. 1 is a graph showing binding of monoclonal antibodies
to mucoid exopolysaccharide antigen (MEP) isolated from P.
aeruginosa strain 2192 M in a direct ELISA as a function of
antibody concentration.
[0030] FIG. 2 is a bar graph showing opsonic killing of mucoid and
non-mucoid P. aeruginosa strains by the monoclonal antibody
F429.gamma.1 at concentrations of 4-25 .mu.g.
[0031] FIG. 3 is a bar graph showing opsonic killing of P.
aeruginosa strains isolated from bacteremic patients as a function
of monoclonal antibody F429.gamma.1 concentration.
[0032] FIG. 4 is a bar graph showing the effects of antibody
administration on mouse survival following challenge with live P.
aeruginosa bacteria.
BRIEF DESCRIPTION OF THE SEQUENCE LISTING
[0033] SEQ ID NO:1 is the nucleotide sequence of the variable
region of the heavy chain from clones F428 and F429.
[0034] SEQ ID NO:2 is the nucleotide sequence of the variable
region of the light chain from clones F428 and F431.
[0035] SEQ ID NO:3 is the nucleotide sequence of the variable
region of the light chain from clones F429 and COMB.
[0036] SEQ ID NO:4 is the nucleotide sequence of the variable
region of the heavy chain from clones F431 and COMB.
[0037] SEQ ID NO:5 is the amino acid sequence of the variable
region of the heavy chain from clones F428 and F429.
[0038] SEQ ID NO:6 is the amino acid sequence of the variable
region of the light chain from clones F428 and F431.
[0039] SEQ ID NO:7 is the amino acid sequence of the variable
region of the light chain from clones F429 and COMB.
[0040] SEQ ID NO:8 is the amino acid sequence of the variable
region of the heavy chain from clones F431 and COMB.
[0041] SEQ ID NO:9 is the nucleotide sequence of CDR1 from SEQ ID
NO:1.
[0042] SEQ ID NO:10 is the nucleotide sequence of CDR2 from SEQ ID
NO:1.
[0043] SEQ ID NO:1 is the nucleotide sequence of CDR3 from SEQ ID
NO:1.
[0044] SEQ ID NO:12 is the nucleotide sequence of CDR1 from SEQ ID
NO:2.
[0045] SEQ ID NO:13 is the nucleotide sequence of CDR2 from SEQ ID
NO:2.
[0046] SEQ ID NO:14 is the nucleotide sequence of CDR3 from SEQ ID
NO:2.
[0047] SEQ ID NO:15 is the nucleotide sequence of CDR1 from SEQ ID
NO:3.
[0048] SEQ ID NO:16 is the nucleotide sequence of CDR2 from SEQ ID
NO:3.
[0049] SEQ ID NO:17 is the nucleotide sequence of CDR3 from SEQ ID
NO:3.
[0050] SEQ ID NO:18 is the nucleotide sequence of CDR1 from SEQ ID
NO:4.
[0051] SEQ ID NO:19 is the nucleotide sequence of CDR2 from SEQ ID
NO:4.
[0052] SEQ ID NO:20 is the nucleotide sequence of CDR3 from SEQ ID
NO:4.
[0053] SEQ ID NO:21 is the amino acid sequence of CDR1 from SEQ ID
NO:5.
[0054] SEQ ID NO:22 is the amino acid sequence of CDR2 from SEQ ID
NO:5.
[0055] SEQ ID NO:23 is the amino acid sequence of CDR3 from SEQ ID
NO:5.
[0056] SEQ ID NO:24 is the amino acid sequence of CDR1 from SEQ ID
NO:6.
[0057] SEQ ID NO:25 is the amino acid sequence of CDR2 from SEQ ID
NO:6.
[0058] SEQ ID NO:26 is the amino acid sequence of CDR3 from SEQ ID
NO:6.
[0059] SEQ ID NO:27 is the amino acid sequence of CDR1 from SEQ ID
NO:7.
[0060] SEQ ID NO:28 is the amino acid sequence of CDR2 from SEQ ID
NO:7.
[0061] SEQ ID NO:29 is the amino acid sequence of CDR3 from SEQ ID
NO:7.
[0062] SEQ ID NO:30 is the amino acid sequence of CDR1 from SEQ ID
NO:8.
[0063] SEQ ID NO:31 is the amino acid sequence of CDR2 from SEQ ID
NO:8.
[0064] SEQ ID NO:32 is the amino acid sequence of CDR3 from SEQ ID
NO:8.
[0065] SEQ ID NO :33 is the nucleotide sequence of FR1 from SEQ ID
NO:1.
[0066] SEQ ID NO:34 is the nucleotide sequence of FR2 from SEQ ID
NO:1.
[0067] SEQ ID NO:35 is the nucleotide sequence of FR3 from SEQ ID
NO:1.
[0068] SEQ ID NO:36 is the nucleotide sequence of FR4 from SEQ ID
NO:1.
[0069] SEQ ID NO:37 is the nucleotide sequence of FR1 from SEQ ID
NO:2.
[0070] SEQ ID NO:38 is the nucleotide sequence of FR2 from SEQ ID
NO:2.
[0071] SEQ ID NO:39 is the nucleotide sequence of FR3 from SEQ ID
NO:2.
[0072] SEQ ID NO:40 is the nucleotide sequence of FR4 from SEQ ID
NO:2.
[0073] SEQ ID NO:41 is the nucleotide sequence of FR1 from SEQ ID
NO:3.
[0074] SEQ ID NO:42 is the nucleotide sequence of FR2 from SEQ ID
NO:3.
[0075] SEQ ID NO:43 is the nucleotide sequence of FR3 from SEQ ID
NO:3.
[0076] SEQ ID NO:44 is the nucleotide sequence of FR4 from SEQ ID
NO:3.
[0077] SEQ ID NO:45 is the nucleotide sequence of FR1 from SEQ ID
NO:4.
[0078] SEQ ID NO:46 is the nucleotide sequence of FR2 from SEQ ID
NO:4.
[0079] SEQ ID NO:47 is the nucleotide sequence of FR3 from SEQ ID
NO:4.
[0080] SEQ ID NO:48 is the nucleotide sequence of FR4 from SEQ ID
NO:4.
[0081] SEQ ID NO:49 is the amino acid sequence of FR1 from SEQ ID
NO:5.
[0082] SEQ ID NO:50 is the amino acid sequence of FR2 from SEQ ID
NO:5.
[0083] SEQ ID NO:51 is the amino acid sequence of FR3 from SEQ ID
NO:5.
[0084] SEQ ID NO:52 is the amino acid sequence of FR4 from SEQ ID
NO:5.
[0085] SEQ ID NO:53 is the amino acid sequence of FR1 from SEQ ID
NO:6.
[0086] SEQ ID NO:54 is the amino acid sequence of FR2 from SEQ ID
NO:6.
[0087] SEQ ID NO:55 is the amino acid sequence of FR3 from SEQ ID
NO:6.
[0088] SEQ ID NO:56 is the amino acid sequence of FR4 from SEQ ID
NO:6.
[0089] SEQ ID NO:57 is the amino acid sequence of FR1 from SEQ ID
NO:7.
[0090] SEQ ID NO:58 is the amino acid sequence of FR2 from SEQ ID
NO:7.
[0091] SEQ ID NO:59 is the amino acid sequence of FR3 from SEQ ID
NO:7.
[0092] SEQ ID NO:60 is the amino acid sequence of FR4 from SEQ ID
NO:7.
[0093] SEQ ID NO:61 is the amino acid sequence of FR1 from SEQ ID
NO:8.
[0094] SEQ ID NO:62 is the amino acid sequence of FR2 from SEQ ID
NO:8.
[0095] SEQ ID NO:63 is the amino acid sequence of FR3 from SEQ ID
NO:8.
[0096] SEQ ID NO:64 is the amino acid sequence of FR4 from SEQ ID
NO:8.
DETAILED DESCRIPTION OF THE INVENTION
[0097] The invention relates to the discovery and synthesis of
peptides that bind to P. aeruginosa mucoid exopolysaccharide (i.e.,
MEP or alginate). Peptides that bind to P. aeruginosa MEP are
referred to herein as MEP-binding peptides. These peptides
preferably contain at least one P. aeruginosa MEP-binding
complementarity determining region (CDR). As used herein, a P.
aeruginosa MEP-binding CDR is a CDR derived from one of the
antibodies recited herein, namely F428, F429, F431 or COMB. Mucoid
strains of P. aeruginosa commonly infect subjects having cystic
fibrosis. MEP is an external polysaccharide produced by mucoid
strains of P. aeruginosa and used by such bacteria in the initial
attachment to epithelia cell surfaces. MEP forms a slime-like
coating around P. aeruginosa colonies in vivo and in vitro. It has
been characterized molecularly as a polymer of uronic acids (e.g.,
mannuronic acid and guluronic acid). Importantly, the presence of a
MEP coating around P. aeruginosa bacterial colonies in vivo renders
these colonies partly resistant to antibiotic therapy.
[0098] Although not intending to be bound by any particular theory,
it is believed that progression of chronic mucoid P. aeruginosa
infection in cystic fibrosis patients is due to a failure to
produce an adequate immune response that eliminates the pathogen.
Specifically, the defect is a failure to produce opsonic antibodies
specific for the MEP capsule of P. aeruginosa. Opsonic antibodies
are antibodies that deposit themselves on an antigen or on a
bacterium with and without complement and facilitate the
phagocytosis of the antigen or bacterium by phagocytic cells such
as antigen presenting cells (e.g., macrophages or dendritic cells).
The ability to provide opsonic antibodies to the site of a P.
aeruginosa infection should contribute to the eradication of mucoid
P. aeruginosa from, for example, the lungs of chronically colonized
cystic fibrosis patients. As used herein, the terms opsonic and
opsonophagocytic are used interchangeably to refer to an antibody
that is able to induce Fc mediated phagocytosis of an antigen such
as a bacterium.
[0099] The invention is premised, in part, on the discovery and
synthesis of human monoclonal antibodies that bind to P. aeruginosa
MEP and enhance opsonophagocytosis of P. aeruginosa (i.e., opsonic
human monoclonal antibodies specific for P. aeruginosa MEP). These
antibodies were produced by molecularly manipulating antibody
encoding genes from B cells harvested from human subjects immunized
with purified MEP. The recombined immunoglobulin (Ig) genes from
these B cells, particularly the variable region genes, were
isolated from the harvested B cells and cloned into an Ig
recombination vector that codes for human Ig constant region genes
of both heavy and light chains. Using this technique, four novel
antibodies that bind to P. aeruginosa MEP and enhance
opsonophagocytosis of P. aeruginosa have been identified and
synthesized. All the antibody clones are of IgG isotype and they
are designated F429, F430, F431 and COMB.
[0100] The antibodies described herein are able to bind to mucoid
and several non-mucoid P. aeruginosa strains. It is believed that
strains characterized as "non-mucoid" still secrete low levels of
MEP sufficient for detection by the peptides. The antibodies are
capable of mediating opsonic killing of P. aeruginosa isolates from
infected human subjects. When used in vivo in murine models of P.
aeruginosa infection, the antibodies provide protection to P.
aeruginosa challenge. These and other findings are described in
greater detail in the Examples.
[0101] The peptides of the invention minimally comprise regions
that bind to MEP (i.e., P. aeruginosa MEP-binding region). P.
aeruginosa MEP-binding regions derive from the MEP-binding regions
of the antibodies of the invention, or alternatively, they are
functionally equivalent variants of such regions. Two particular
classes of antibody derived P. aeruginosa MEP-binding regions are
variable regions and complementarity determining regions (CDRs).
Both variable regions and CDRs may easily be sequenced by one of
ordinary skill in the art. A description of these regions is
provided below as is the location of these regions in the
antibodies and sequences of the invention.
[0102] An antibody, as is well known in the art, is an assembly of
polypeptide chains linked by disulfide bridges. Two principle
polypeptide chains, referred to as the light chain and heavy chain,
make up all major structural classes (isotypes) of antibody. Both
heavy chains and light chains are further divided into subregions
referred to as variable regions and constant regions. In some
instances, the peptides encompass the antibody heavy and light
variable chains of the foregoing antibodies. The heavy chain
variable region is a peptide which generally ranges from 100 to 150
amino acids in length. The light chain variable region is a peptide
which generally ranges from 80 to 130 amino acids in length. The
present invention provides four different variable regions, two of
which are heavy chain variable regions and two of which are light
chain variable regions. SEQ ID NO:1 and SEQ ID NO:5 correspond to
the nucleotide and amino acid sequence of the heavy chain variable
region derived from antibody clones F428 and F429. SEQ ID NO:2 and
SEQ ID NO:6 correspond to the nucleotide and amino acid sequence of
the light chain variable region derived from antibody clones F428
and F431. SEQ ID NO:3 and SEQ ID NO:7 correspond to the nucleotide
and amino acid sequence of the light chain variable region derived
from antibody lone F429. SEQ ID NO:4 and SEQ ID NO:8 correspond to
the nucleotide and amino acid sequence of the heavy chain variable
region derived from antibody clone F431.
[0103] Alternatively, the peptides encompass only the
complementarity determining regions (i.e., CDRs) of the foregoing
variable regions. As is well-known in the art, CDRs of an antibody
are the portions of the antibody which are largely responsible for
antibody specificity. The CDRs directly interact with the epitope
of the antigen (see, in general, Clark, 1986; Roitt, 1991). In both
the heavy chain and the light chain variable regions of IgG
immunoglobulins, there are four framework regions (FR1 through FR4)
separated respectively by three complementarity determining regions
(CDR1, CDR2 and CDR3). The framework regions (FRs) maintain the
tertiary structure of the paratope, which is the portion of the
antibody which is involved in the interaction with the antigen.
CDRs, and in particular CDR3, and more particularly heavy chain
CDR3, contribute to antibody specificity. Because CDRs, and in
particular CDR3, confer antigen specificity on the antibody, these
regions may be incorporated into other antibodies or peptides to
confer the identical antigen specificity onto that antibody or
peptide.
[0104] The P. aeruginosa MEP-binding region may be a P. aeruginosa
MEP-binding CDR1, a P. aeruginosa MEP-binding CDR2, or a P.
aeruginosa MEP-binding CDR3, all of which are derived from the
antibodies and antibody variable chains disclosed herein. As used
herein, a "P. aeruginosa MEP-binding CDR1" is a CDR1 that binds,
preferably specifically, to P. aeruginosa MEP, and is derived from
either the heavy or light chain variable regions of the antibodies
described herein. It preferably has an amino acid sequence selected
from the group consisting of SEQ ID NO:21, SEQ ID NO:24, SEQ ID
NO:27 and SEQ ID NO:30. Similar respective definitions apply to P.
aeruginosa binding CDR2 and CDR3. A "P. aeruginosa MEP-binding
CDR2" is a CDR2 that binds, preferably specifically, to P.
aeruginosa MEP, and is derived from either the heavy or light chain
variable regions of the antibodies described herein. It has an
amino acid sequence selected from the group consisting of SEQ ID
NO:22, SEQ ID NO:25, SEQ ID NO:28 and SEQ ID NO:31. A "P.
aeruginosa MEP-binding CDR3" is a CDR3 that binds, preferably
specifically, to P. aeruginosa MEP, and is derived from either the
heavy or light chain variable regions of the antibodies described
herein. It preferably has an amino acid sequence selected from the
group consisting of SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:29 and
SEQ ID NO:32. In addition to the sequences listed above, the
invention intends to embrace functionally equivalent variants of
these sequences including conservative substitution variants, as
described in greater detail below.
[0105] The peptides of the invention, including but not limited to
the opsonophagocytic antibodies discussed herein, are useful inter
alia in diagnostic methods aimed at detecting P. aeruginosa
bacteria in a sample in or from a subject. At a minimum, peptides
useful in these methods need only recognize and bind to P.
aeruginosa MEP, regardless of whether they also enhance
opsonization and phagocytosis. In important embodiments, the
antibodies and fragments thereof bind to MEP selectively.
Accordingly, they need only possess one or more of the CDRs derived
from the antibody clones described herein. In preferred embodiment,
the peptides comprise a MEP-binding CDR3, and even more preferably,
the peptides comprise a heavy chain MEP-binding CDR3. It is to be
understood that not all of the CDRs are required in order to effect
binding to P. aeruginosa MEP. However, in some embodiments the
peptides comprise all of the CDRs disclosed herein.
[0106] In addition, it should be understood that the invention also
embraces the exchange of CDRs between the variable regions provided
herein. Preferably, a heavy chain CDR is exchanged with another
heavy chain variable region CDR, and likewise, a light chain CDR is
exchanged with another light chain variable region CDR.
[0107] The nucleotide sequences of the CDRs of the variable chains
disclosed in the present invention are as follows: TABLE-US-00001
Clone Chain CDR SEQ ID NO: Sequence F428 Hv CDR1 9 TAT ATT AAT TAC
TAG TGG GGC F428 Hv CDR2 10 AGT ATG CAT TAT GAT GGG AGG ACC TTG TAG
AAC CCG TCC CTC AAG AGT F428 Hv CDR3 11 ACG TAT TAC GAT GCT TCG GGG
AGC CCT TAC TTT GAC CAC F428 Lt CDR1 12 TCT GGA AGC AGC TCC AAC CTT
GGG AAC AAT TTT GTA TCC F428 Lt CDR2 13 GAC AAT GAT AAG CGA CCC TCA
F428 Lt CDR3 14 GGA ACA TGG GAT AGC AGC CTG ACT GCT TAT GTC F429 Lt
CDR1 15 TCT GGA AGC AGC TCC AAC ATT GGG AAT AAT TAT GTA TCC F429 Lt
CDR2 16 GAC AAT AAT AAG CGA CCC TCA F429 Lt CDR3 17 GGA ACA TGG GAT
AGC AGC CTG AGT ACT TGG GTG F431 Hv CDR1 18 AGT AAT AAT TAC TAC TGG
GGC F431 Hv CDR2 19 ACT ATC TCT TAT AAT GGG TAC ACC TAC TAC ATC CCG
TCC CTC AGG GGT F431 Hv CDR3 20 CAT GAC TAT AGC ATG TCG TCG GGA CTT
ACT GAC AAC TGG TTC GAC CCC
[0108] The amino acid sequences of the CDRs of the variable chains
disclosed in the present invention are as follows: TABLE-US-00002
Clone Chain CDR SEQ ID NO: Sequence F428 Hv CDR1 21 YINYYWG F428 Hv
CDR2 22 SIHYDGSTFYNPSLKS F428 Hv CDR3 23 TYYDASGSPYFDH F428 Lt CDR1
24 SGSSSNLGNNFVS F428 Lt CDR2 25 DNDKRPS F428 Lt CDR3 26
GTWDSSLTAYV F429 Lt CDR1 27 SGSSSNIGNNYVS F429 Lt CDR2 28 DNNKRPS
F429 Lt CDR3 29 GTWDSSLSTWV F431 Hv CDR1 30 SNNYYWG F431 Hv CDR2 31
TISYNGYTYYIPSLRG F431 Hv CDR3 32 HDYSMSSGLTDNWFDP
[0109] As used herein, the term "peptide" includes monoclonal
antibodies, functionally active and/or equivalent antibody
fragments, and functionally active and/or equivalent peptides and
polypeptides. The peptides of the invention are isolated peptides.
As used herein, the term "isolated peptides" means that the
peptides are substantially pure and are essentially free of other
substances with which they may be found in nature or in vivo
systems to an extent practical and appropriate for their intended
use. In particular, the peptides are sufficiently pure and are
sufficiently free from other biological constituents of their hosts
cells so as to be useful in, for example, producing pharmaceutical
preparations or sequencing. Because an isolated peptide of the
invention may be admixed with a pharmaceutically acceptable carrier
in a pharmaceutical preparation, the peptide may comprise only a
small percentage by weight of the preparation. The peptide is
nonetheless substantially pure in that it has been substantially
separated from the substances with which it may be associated in
living systems.
[0110] The peptides of the invention bind to MEP, preferably in a
selective manner. As used herein, the terms "selective binding" and
"specific binding" are used interchangeably to refer to the ability
of the peptide to bind with greater affinity to MEP and fragments
thereof than to non-MEP derived compounds. That is, peptides that
bind selectively to MEP will not bind to non-MEP derived compounds
to the same extent and with the same affinity as they bind to MEP
and fragments thereof. In preferred embodiments, the peptides of
the invention bind solely to MEP and fragments thereof.
[0111] As stated earlier, the invention provides peptides e.g.,
antibodies or antibody fragments, that bind to P. aeruginosa MEP.
Such antibodies preferably enhance opsonization and phagocytosis
(i.e., opsonophagocytosis) of P. aeruginosa, and as a result are
useful in the prevention and therapy of a P. aeruginosa infection
in a subject. Opsonization refers to a process by which
phagocytosis is facilitated by the deposition of opsonins (e.g.,
antibody or complement factor C3b) on the antigen. Phagocytosis
refers to the process by which phagocytic cells (e.g., macrophages,
dendritic cells, and polymorphonuclear leukocytes (PMNL)) engulf
material and enclose it within a vacuole (e.g., a phagosome) in
their cytoplasm. Thus, antibodies or antibody fragments that
enhance opsonization and phagocytosis are antibodies or antibody
fragments that recognize and deposit onto an antigen, and in doing
so, facilitate the uptake and engulfment of the antigen (and the
antigen-bearing substance, e.g., P. aeruginosa bacteria) by
phagocytic cells. Generally, in order to enhance phagocytosis and
opsonization, the antibody comprises an Fc domain or region. The Fc
domain is recognized by Fc receptor bearing cells (e.g., antigen
presenting cells such as macrophages, or PMNL). As used herein, "to
enhance opsonophagocytosis" means to increase the likelihood that
an antigen or an antigen bearing substrate will be recognized and
engulfed by a phagocytic cell, via antibody deposition. This
enhancement can be measured by reduction in bacterial load in vivo
or by bacterial cell killing in vitro using the in vitro methods
described below.
[0112] Opsonization assays are standard in the art. Generally such
assays measure the amount of bacterial killing in the presence of
an antibody, an antigen (expressed on the target bacterial cell),
complement, and phagocytic cells. Serum is commonly used as a
source of complement, and polymorphonuclear cells are commonly used
as a source of phagocytic cells. The target cell source can be
prokaryotic (as in the present invention) or eukaryotic, depending
upon which cell type expresses the antigen. Cell killing can be
measured by viable cell counts prior to and following incubation of
the reaction components. Alternatively, cell killing can be
quantitated by measuring labeled cell contents in the supernatant
of the reaction mixture (i.e., chromium release). Other assays will
be apparent to those of skill in the art, having read the present
specification, which are useful for determining whether an antibody
or antibody fragment that binds to P. aeruginosa MEP also
stimulates opsonization and phagocytosis.
[0113] The present invention provides, inter alia, MEP-specific
human monoclonal antibodies that enhance opsonic killing of mucoid
P. aeruginosa. These antibodies are named F428, F429, F431 and
COMB. When used in vivo, human monoclonal antibodies are far less
likely to be immunogenic (as compared to antibodies from another
species). As a result, these antibodies represent novel agents
useful in the design of vaccines as well as passive immunotherapy
targeting P. aeruginosa. The synthesis of these monoclonal
antibodies is described in the Examples. Briefly, the antibodies
were derived from B cells harvested from individuals immunized with
MEP as described in U.S. Pat. 4,578,458. Harvested B cells were
transformed using Epstein-Barr virus, and then fused with an
immortalized cell line fusion partner called HMMA 2.5. Single
antibody producing clones were grown and analyzed separately using
a binding assay (e.g., ELISA). Three antibodies were selected based
on their ability to bind to P. aeruginosa MEP. All three antibodies
were of IgA isotype. cDNA coding for the heavy and light variable
regions of the three antibodies was then isolated and sequenced.
Variable region cDNA was cloned into an human Ig expression vector
(i.e., TCAE 5.3) that contained Ig constant region coding sequences
for both heavy and light chains. These expression vectors were then
transfected into cells (e.g., CHO DG44 cells), the cells were grown
in vitro, and Ig was subsequently harvested from the supernatant.
Resultant antibodies possessed human variable regions and human IgG
constant regions. Their ability to bind to P. aeruginosa,
specifically to P. aeruginosa MEP, and to enhance opsonization and
phagocytosis of P. aeruginosa was evaluated using binding and
opsonophagocytic killing assays such as those described herein.
[0114] Thus in one embodiment, the peptide of the invention is an
isolated intact soluble monoclonal antibody specific for P.
aeruginosa MEP. As used herein, the term "monoclonal antibody"
refers to a homogenous population of immunoglobulins that
specifically bind to an identical epitope (i.e., antigenic
determinant). The peptide of the invention in one embodiment is,
for example, a monoclonal antibody having a heavy chain variable
region having an amino acid sequence of SEQ ID NO:5. In another
embodiment, the monoclonal antibody has a heavy chain variable
region having an amino acid sequence of SEQ ID NO:8. The monoclonal
antibody can have a light chain variable region having an amino
acid sequence of SEQ ID NO:6 or SEQ ID NO:7. Monoclonal antibodies
having any combination of light chain and heavy chain variable
regions are embraced by the invention. Using the nomenclature set
forth in the Examples for denoting heavy and light chain variable
regions and their corresponding amino acid and nucleic acid
sequences, the following combinations can be included in a
monoclonal antibody of the invention: heavy chain A (SEQ ID NO:5)
and light chain 1 (SEQ ID NO:6); heavy chain A (SEQ ID NO:5) and
light chain 2 (SEQ ID NO:7); heavy chain B (SEQ ID NO:8) and light
chain 1 (SEQ ID NO:6); and heavy chain B (SEQ ID NO:8) and light
chain 2 (SEQ ID NO:7).
[0115] The invention intends to encompass antibodies other than for
example clones F428, F429, F431 and COMB, provided that such
antibodies have the binding characteristics of the monoclonal
antibodies described herein. Optionally, these additional
antibodies also enhance opsonophagocytosis of P. aeruginosa cells.
One of ordinary skill in the art can easily identify antibodies
having the functional characteristics (e.g., binding, opsonizing
and phagocytosing attributes) of these monoclonal antibody using
the screening and binding assays set forth in detail herein.
[0116] In other embodiments, the peptide is an antibody fragment.
As is well-known in the art, only a small portion of an antibody
molecule, the paratope, is involved in the binding of the antibody
to its epitope (see, in general, Clark, W. R. (1986) The
Experimental Foundations of Modern Immunology Wiley & Sons,
Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed.,
Blackwell Scientific Publications, Oxford). The pFc' and Fc regions
of the antibody, for example, are effectors of the complement
cascade but are not involved in antigen binding. An antibody from
which the pFc' region has been enzymatically cleaved, or which has
been produced without the pFc' region, designated an F(ab').sub.2
fragment, retains both of the antigen binding sites of an intact
antibody. An isolated F(ab').sub.2 fragment is referred to as a
bivalent monoclonal fragment because of its two antigen binding
sites. Similarly, an antibody from which the Fc region has been
enzymatically cleaved, or which has been produced without the Fc
region, designated an Fab fragment, retains one of the antigen
binding sites of an intact antibody molecule. Proceeding further,
Fab fragments consist of a covalently bound antibody light chain
and a portion of the antibody heavy chain denoted Fd (heavy chain
variable region). The Fd fragments are the major determinant of
antibody specificity (a single Fd fragment may be associated with
up to ten different light chains without altering antibody
specificity) and Fd fragments retain epitope-binding ability in
isolation.
[0117] The terms Fab, Fc, pFc', F(ab').sub.2 and Fv are employed
with either standard immunological meanings [Klein, Immunology
(John Wiley, New York, N.Y., 1982); Clark, W. R. (1986) The
Experimental Foundations of Modern Immunology (Wiley & Sons,
Inc., New York); Roitt, I. (1991) Essential Immunology, 7th Ed.,
(Blackwell Scientific Publications, Oxford)].
[0118] In other embodiments, the Fc portions of the antibodies of
the invention may be replaced so as to produce IgM as well as human
IgG antibodies bearing some or all of the CDRs of the monoclonal
antibodies described herein. Of particular importance is the
inclusion of a P. aeruginosa MEP-binding CDR3 region and, to a
lesser extent, the other CDRs and portions of the framework regions
of the monoclonal antibodies described herein. Such human
antibodies will have particular clinical utility in that they will
recognize and bind, preferably selectively, to P. aeruginosa MEP,
but will not evoke an immune response in humans against the
antibody itself.
[0119] The invention also intends to include functionally
equivalent variants of the P. aeruginosa MEP-binding peptides. A
"functionally equivalent variant" is a compound having the same
function (i.e., the ability to bind to P. aeruginosa MEP and in
some embodiments to facilitate opsonization of the bacterium) as
the peptides of the invention. A functionally equivalent variant
may be peptide in nature but it is not so limited. For example, it
may be a carbohydrate, a peptidomimetic, etc. In important
embodiments, the functionally equivalent variant is a peptide
having the amino acid sequence of a variable region or a CDR with
conservative substitutions therein, that is still capable of
binding to P. aeruginosa MEP. An example of a functionally
equivalent variant of P. aeruginosa MEP-binding CDR3 from the heavy
chain variable region of clone F428 (i.e., SEQ ID NO:5) is a
peptide having conservative substitutions in SEQ ID NO:5 which
bind, preferably specifically, to P. aeruginosa MEP, and optionally
which enhances opsonization of P. aeruginosa. As used herein,
"conservative substitution" refers to an amino acid substitution
which does not alter the relative charge or size characteristics of
the peptide in which the amino acid substitution is made.
Conservative substitutions of amino acids include substitutions
made amongst amino acids with the following groups: (I) M,I,L,V;
(2) F,Y,W; (3) K,R,H; (4) A,G; (5) S,T; (6) Q,N; and, (7) E,D.
[0120] Functional equivalent variants can have identity to the
peptides explicitly recited herein. That is, such variants may have
at least 99% identity, at least 98% identity, at least 97%
identity, at least 96% identity, at least 95% identity, at least
94% identity, at least 93% identity, at least 92% identity, at
least 91% identity, at least 90% identity, at least 85% identity,
at least 80% identity, at least 75% identity, at least 70%
identity, at least 65% identity, at least 60% identity, at least
55% identity, at least 50% identity, at least 45% identity, at
least 40% identity, at least 35% identity, at least 30% identity,
at least 25% identity, at least 20% identity, at least 10%
identity, or at least 5% identity to the amino acid sequences
provided herein.
[0121] Functional equivalence refers to an equivalent activity
(e.g., binding to P. aeruginosa MEP, or enhancing
opsonophagocytosis of P. aeruginosa), however it also embraces
variation in the level of such activity. For example, a functional
equivalent is a variant that binds to P. aeruginosa MEP with
lesser, equal, or greater affinity than the monoclonal antibody
clones described herein, provided that the variant is still useful
in the invention (i.e., it binds to P. aeruginosa MEP and
optionally enhances opsonophagocytosis of P. aeruginosa).
[0122] Such substitutions can be made by a variety of methods known
to one of ordinary skill in the art. For example, amino acid
substitutions may be made by PCR-directed mutation, site-directed
mutagenesis according to the method of Kunkel (Kunkel, Proc. Nat.
Acad. Sci. USA 82: 488-492, 1985), or by chemical synthesis of a
gene encoding the particular CDR. These and other methods for
altering a CDR containing peptide will be known to those of
ordinary skill in the art and may be found in references which
compile such methods, e.g. Sambrook or Ausubel, noted above. In
some embodiments, however, due to the size of the CDRs, it may be
more convenient to synthesize the variant peptides using a peptide
synthesizer such as those commercially available. The activity of
functionally equivalent variants of the P. aeruginosa MEP-binding
CDR can be tested by the binding assays, and in some cases
biological activity assays, as discussed in more detail below. As
used herein, the terms "functional variant", "functionally
equivalent variant" and "functionally active variant" are used
interchangeably.
[0123] As used herein the term "functionally active antibody
fragment" means a fragment of an antibody molecule including a P.
aeruginosa MEP-binding region of the invention which retains the
ability to bind to P. aeruginosa MEP, preferably in a specific
manner. Such fragments can be used both in vitro and in vivo. In
particular, well-known functionally active antibody fragments
include but are not limited to F(ab').sub.2, Fab, Fv and Fd
fragments of antibodies. These fragments which lack the Fc fragment
of intact antibody, clear more rapidly from the circulation, and
may have less non-specific tissue binding than an intact antibody
(Wahl et al., J. Nucl. Med. 24:316-325 (1983)). As another example,
single-chain antibodies can be constructed in accordance with the
methods described in U.S. Pat. No. 4,946,778 to Ladner et al. Such
single-chain antibodies include the variable regions of the light
and heavy chains joined by a flexible linker moiety. Methods for
obtaining a single domain antibody ("Fd") which comprises an
isolated variable heavy chain single domain, also have been
reported (see, for example, Ward et al., Nature 341:644-646 (1989),
disclosing a method of screening to identify an antibody heavy
chain variable region (V.sub.H single domain antibody) with
sufficient affinity for its target epitope to bind thereto in
isolated form). Methods for making recombinant Fv fragments based
on known antibody heavy chain and light chain variable region
sequences are known in the art and have been described, e.g., Moore
et al., U.S. Pat. No.4,462,334. Other references describing the use
and generation of antibody fragments include e.g., Fab fragments
(Tijssen, Practice and Theory of Enzyme Immunoassays (Elsevier,
Amsterdam, 1985)), Fv fragments (Hochman et al., Biochemistry 12:
1130 (1973); Sharon et al., Biochemistry 15: 1591 (1976); Ehrlich
et al., U.S. Pat. No. 4,355,023) and portions of antibody molecules
(Audilore-Hargreaves, U.S. Pat. No. 4,470,925). Thus, those skilled
in the art may construct antibody fragments from various portions
of intact antibodies without destroying the specificity of the
antibodies for the P. aeruginosa MEP epitope.
[0124] In important aspects of the invention, the functionally
active antibody fragment also retains the ability to opsonize and
phagocytose P. aeruginosa. In this latter instance, the antibody
fragment includes an Fc region as well as an epitope binding
domain. The Fc region allows the antibody fragment to bind to Fc
receptor positive cells, which subsequently phagocytose the epitope
bound by the Fab region of the antibody.
[0125] Still other screening assays for identifying peptides of the
invention are performed for example, using phage display procedures
such as those described in Hart, et al., J. Biol. Chem. 269:12468
(1994). Hart et al. report a filamentous phage display library for
identifying novel peptide ligands for mammalian cell receptors. In
general, phage display libraries using, e.g., M13 or fd phage, are
prepared using conventional procedures such as those described in
the foregoing reference. The libraries display inserts containing
from 4 to 80 amino acid residues. The inserts optionally represent
a completely degenerate or a biased array of peptides. Ligands that
bind, preferably selectively, to P. aeruginosa MEP are obtained by
selecting those phages which express on their surface a ligand that
binds to P. aeruginosa MEP. These phages then are subjected to
several cycles of reselection to identify the peptide
ligand-expressing phages that have the most useful binding
characteristics. Typically, phages that exhibit the best binding
characteristics (e.g., highest affinity) are further characterized
by nucleic acid analysis to identify the particular amino acid
sequences of the peptides expressed on the phage surface and the
optimum length of the expressed peptide to achieve optimum binding
to P. aeruginosa MEP. Alternatively, such peptide ligands can be
selected from combinatorial libraries of peptides containing one or
more amino acids. Such libraries can further be synthesized which
contain non-peptide synthetic moieties which are less subject to
enzymatic degradation compared to their naturally-occurring
counterparts.
[0126] Additionally small peptides including those containing the
P. aeruginosa MEP-binding CDR3 region may easily be synthesized or
produced by recombinant means to produce the peptide of the
invention. Such methods are well known to those of ordinary skill
in the art. Peptides can be synthesized for example, using
automated peptide synthesizers which are commercially available.
The peptides can be produced by recombinant techniques by
incorporating the DNA expressing the peptide into an expression
vector and transforming cells with the expression vector to produce
the peptide.
[0127] Peptides, including antibodies, can be tested for their
ability to bind to P. aeruginosa MEP using standard binding assays
known in the art. As an example of a suitable assay, P. aeruginosa
MEP can be immobilized on a surface (such as in a well of a
multi-well plate) and then contacted with a labeled peptide. The
amount of peptide that binds to the P. aeruginosa MEP (and thus
becomes itself immobilized onto the surface) may then be
quantitated to determine whether a particular peptide binds to P.
aeruginosa MEP. Alternatively, the amount of peptide not bound to
the surface may also be measured. In a variation of this assay, the
peptide can be tested for its ability to bind directly to a P.
aeruginosa colony grown in vitro. An example of this latter assay
is described in greater detail in the Examples.
[0128] Peptide binding can also be tested using a competition
assay. If the peptide being tested competes with the monoclonal
antibodies or antibody fragments described herein, as shown by a
decrease in binding of the monoclonal antibody or fragment, then it
is likely that the peptide and the monoclonal antibody bind to the
same, or at least an overlapping, epitope. In this assay system,
the antibody or antibody fragment is labeled and the P. aeruginosa
MEP is immobilized onto the solid surface. These and other assays
are described in more detail herein.
[0129] Standard binding assays are well known in the art, and a
number of these are suitable in the present invention including
ELISA, competition binding assay (as described above), sandwich
assays, radioreceptor assays using radioactively labeled peptides
or radiolabeled antibodies, immunoassays, etc. The nature of the
assay is not essential provided it is sufficiently sensitive to
detect binding of a small number of peptides.
[0130] A variety of other reagents also can be included in the
binding mixture. These include reagents such as salts, buffers,
neutral proteins (e.g., albumin), detergents, etc. which may be
used to facilitate optimal binding. Such a reagent may also reduce
non-specific or background interactions of the reaction components.
Other reagents that improve the efficiency of the assay may also be
used. The mixture of the foregoing assay materials is incubated
under conditions under which the monoclonal antibody normally
specifically binds P. aeruginosa MEP. Such conditions will
preferably mimic physiological conditions. The order of addition of
components, incubation temperature, time of incubation, and other
parameters of the assay may be readily determined. Such
experimentation merely involves optimization of the assay
parameters, not the fundamental composition of the assay.
Incubation temperatures typically are between 4.degree. C. and
40.degree. C. Incubation times preferably are minimized to
facilitate rapid, high throughput screening, and typically are
between 0.1 and 10 hours. After incubation, the presence or absence
of specific binding between the peptide and P. aeruginosa MEP is
detected by any convenient method available to the user.
[0131] Typically, a plurality of assay mixtures are run in parallel
with different peptides or different peptide concentrations to
obtain a different response to the various concentrations. One of
these concentrations serves as a negative control, i.e., at zero
concentration of P. aeruginosa MEP or at a concentration of P.
aeruginosa MEP below the limits of assay detection.
[0132] A separation step is often used to separate bound from
unbound peptide or antibody. The separation step may be
accomplished in a variety of ways. Conveniently, at least one of
the components (e.g., peptide or antibody) is immobilized on a
solid substrate via binding to P. aeruginosa MEP. The unbound
components may be easily separated from the bound fraction. The
solid substrate can be made of a wide variety of materials and in a
wide variety of shapes, e.g., columns or gels of polyacrylamide,
agarose or sepharose, microtiter plates, microbeads, resin
particles, etc. The separation step preferably includes multiple
rinses or washes. For example, when the solid substrate is a
microtiter plate, the wells may be washed several times with a
washing solution, which typically includes those components of the
incubation mixture that do not participate in specific bindings
such as salts, buffer, detergent, non-specific protein, etc. Where
the solid substrate is a magnetic bead, the beads may be washed one
or more times with a washing solution and isolated using a
magnet.
[0133] The peptides can be used alone or in conjugates with other
molecules such as detection or cytotoxic agents in the detection
and treatment methods of the invention, as described in more detail
herein.
[0134] Typically, one of the components usually comprises, or is
coupled or conjugated to a detectable label. A detectable label is
a moiety, the presence of which can be ascertained directly or
indirectly. Generally, detection of the label involves an emission
of energy by the label. The label can be detected directly by its
ability to emit and/or absorb light of a particular wavelength
(e.g., radioactivity, luminescence, optical or electron density,
etc.). A label can be detected indirectly by its ability to bind,
recruit and, in some cases, cleave another moiety which itself may
emit or absorb light of a particular wavelength (e.g., epitope tag
such as the FLAG epitope, enzyme tag such as horseradish
peroxidase, etc.). An example of indirect detection is the use of a
first enzyme label which cleaves a substrate into visible products.
The label may be of a chemical, peptide or nucleic acid molecule
nature although it is not so limited. Other detectable labels
include radioactive isotopes such as P.sup.32 or H.sup.3,
luminescent markers such as fluorochromes, optical or electron
density markers, etc., or epitope tags such as the FLAG epitope or
the HA epitope, biotin, avidin, and enzyme tags such as horseradish
peroxidase, .beta.-galactosidase, etc. The label may be bound to a
peptide during or following its synthesis. There are many different
labels and methods of labeling known to those of ordinary skill in
the art. Examples of the types of labels that can be used in the
present invention include enzymes, radioisotopes, fluorescent
compounds, colloidal metals, chemiluminescent compounds, and
bioluminescent compounds. Those of ordinary skill in the art will
know of other suitable labels for the peptides described herein, or
will be able to ascertain such, using routine experimentation.
Furthermore, the coupling or conjugation of these labels to the
peptides of the invention can be performed using standard
techniques common to those of ordinary skill in the art.
[0135] Another labeling technique which may result in greater
sensitivity consists of coupling the peptides to low molecular
weight haptens. These haptens can then be specifically altered by
means of a second reaction. For example, it is common to use
haptens such as biotin, which reacts with avidin, or dinitrophenol,
pyridoxal, or fluorescein, which can react with specific
anti-hapten antibodies.
[0136] Conjugation of the peptides including antibodies or
fragments thereof to a detectable label facilitates, among other
things, the use of such agents in diagnostic assays. Another
category of detectable labels includes diagnostic and imaging
labels such as for magnetic resonance imaging (MRI): Gd(DOTA); for
nuclear medicine: .sup.201Tl, gamma-emitting radionuclide 99mTc;
for positron-emission tomography (PET): positron-emitting isotopes,
(18)F-fluorodeoxyglucose ((18)FDG), (18)F-fluoride, copper-64,
gadodiamide, and radioisotopes of Pb(II) such as 203Pb; 111In.
[0137] The conjugations or modifications described herein employ
routine chemistry, which chemistry does not form a part of the
invention and which chemistry is well known to those skilled in the
art of chemistry. The use of protecting groups and known linkers
such as mono-and hetero-bifunctional linkers are well documented in
the literature and will not be repeated here.
[0138] As used herein, "conjugated" means two entities stably bound
to one another by any physiochemical means. It is important that
the nature of the attachment is such that it does not impair
substantially the effectiveness of either entity. Keeping these
parameters in mind, any covalent or non-covalent linkage known to
those of ordinary skill in the art may be employed. In some
embodiments, covalent linkage is preferred. Noncovalent conjugation
includes hydrophobic interactions, ionic interactions, high
affinity interactions such as biotin-avidin and biotin-streptavidin
complexation and other affinity interactions. Such means and
methods of attachment are well known to those of ordinary skill in
the art.
[0139] A variety of methods may be used to detect the label,
depending on the nature of the label and other assay components.
For example, the label may be detected while bound to the solid
substrate or subsequent to separation from the solid substrate.
Labels may be directly detected through optical or electron
density, radioactive emissions, nonradiative energy transfers, etc.
or indirectly detected with antibody conjugates,
streptavidin-biotin conjugates, etc. Methods for detecting the
labels are well known in the art.
[0140] The monoclonal antibodies described herein can also be used
to produce anti-idiotypic antibodies that can be used to screen and
identify other antibodies having the same binding specificity as
the monoclonal antibodies of the invention. An anti-idiotypic
antibody is an antibody which recognizes unique determinants
present on a monoclonal antibody of the invention. These
determinants are located in the hypervariable region of the
antibody. It is this region that binds to a given epitope and is
thereby responsible for the specificity of the antibody. Such
anti-idiotypic antibodies can be produced using well-known
hybridoma techniques (Kohler and Milstein, Nature, 256:495, 1975).
As an example, an anti-idiotypic antibody can be prepared by
immunizing a subject with the monoclonal antibody. The immunized
subject will recognize and respond to the idiotypic determinants of
the immunizing monoclonal antibody and produce an antibody to these
idiotypic determinants. By using the anti-idiotypic antibodies of
the immunized animal, which are specific for the monoclonal
antibody of the invention, it is possible to identify other clones
with the same idiotype as the monoclonal antibody used for
immunization. Idiotypic identity between monoclonal antibodies of
two cell lines demonstrates that the two monoclonal antibodies are
the same with respect to their recognition of the same epitopic
determinant. Thus, by using anti-idiotypic antibodies, it is
possible to identify other hybridomas expressing monoclonal
antibodies having the same epitopic specificity.
[0141] The anti-idiotypic antibodies can also be used for active
immunization (Herlyn, et al., Science, 232:100, 1986), since it is
possible to use the anti-idiotype technology to produce monoclonal
antibodies that mimic an epitope. For example, an anti-idiotypic
monoclonal antibody made to a first monoclonal antibody will have a
binding domain in the hypervariable region which is the image of
the epitope bound by the first monoclonal antibody. Thus, the
anti-idiotypic monoclonal antibody can be used for immunization,
since the anti-idiotype monoclonal antibody binding domain
effectively acts as an antigen.
[0142] The sequences responsible for the specificity of the
monoclonal antibodies of the invention have been determined.
Accordingly, peptides according to the invention can be prepared
using recombinant DNA technology. There are entities in the United
States which will perform this function commercially, such as
Thomas Jefferson University and the Scripps Protein and Nucleic
Acids Core Sequencing Facility (La Jolla, Calif.). For example, the
variable region cDNA can be prepared by polymerase chain reaction
from the deposited hybridoma RNA using degenerate or non-degenerate
primers (derived from the amino acid sequence). The cDNA can be
subcloned to produce sufficient quantities of double stranded DNA
for sequencing by conventional sequencing reactions or
equipment.
[0143] With knowledge of the nucleic acid sequences of the heavy
chain and light chain variable domains of the P. aeruginosa MEP
monoclonal antibody, one of ordinary skill in the art is able to
produce nucleic acids which encode this antibody or which encode
the various antibody fragments, humanized antibodies, or
polypeptides described above. It is contemplated that such nucleic
acids will be operably joined to other nucleic acids forming a
recombinant vector for cloning or for expression of the peptides of
the invention. The present invention includes any recombinant
vector containing the coding sequences, or part thereof, whether
for prokaryotic or eukaryotic transformation, transfection or gene
therapy. Such vectors may be prepared using conventional molecular
biology techniques, known to those with skill in the art, and would
comprise DNA coding sequences for the CDR region (and preferably
the CDR3 region) and additional variable sequences contributing to
the specificity of the antibodies or parts thereof, as well as
other non-specific peptide sequences and a suitable promoter either
with (Whittle et al., Protein Eng. 1:499, 1987 and Burton et al.,
Science 266:1024-1027, 1994) or without (Marasco et al., Proc.
Natl. Acad. Sci. (USA) 90:7889, 1993 and Duan et al., Proc. Natl.
Acad. Sci. (USA) 91:5075-5079,1994) a signal sequence for export or
secretion. Such vectors may be transformed or transfected into
prokaryotic (Huse et al., Science 246:1275, 1989, Ward et al.,
Nature 341: 644-646, 1989; Marks et al., J. Mol. Biol. 222:581,
1991 and Barbas et al., Proc. Natl. Acad. Sci. (USA) 88:7978, 991)
or eukaryotic (Whittle et al., 1987 and Burton et al., 1994) cells
or used for gene therapy (Marasco et al., 1993 and Duan et al.,
1994) by conventional techniques, known to those with skill in the
art.
[0144] As used herein, a "vector" may be any of a number of nucleic
acids into which a desired sequence may be inserted by restriction
and ligation for transport between different genetic environments
or for expression in a host cell. Vectors are typically composed of
DNA although RNA vectors are also available. Vectors include, but
are not limited to, plasmids and phagemids. A cloning vector is one
which is able to replicate in a host cell, and which is further
characterized by one or more endonuclease restriction sites at
which the vector may be cut in a determinable fashion and into
which a desired DNA sequence may be ligated such that the new
recombinant vector retains its ability to replicate in the host
cell. In the case of plasmids, replication of the desired sequence
may occur many times as the plasmid increases in copy number within
the host bacterium or just a single time per host before the host
reproduces by mitosis. In the case of phage, replication may occur
actively during a lytic phase or passively during a lysogenic
phase. An expression vector is one into which a desired DNA
sequence may be inserted by restriction and ligation such that it
is operably joined to regulatory sequences and may be expressed as
an RNA transcript. Vectors may further contain one or more marker
sequences suitable for use in the identification of cells which
have or have not been transformed or transfected with the vector.
Markers include, for example, genes encoding proteins which
increase or decrease either resistance or sensitivity to
antibiotics or other compounds, genes which encode enzymes whose
activities are detectable by standard assays known in the art
(e.g., .beta.-galactosidase or alkaline phosphatase), and genes
which visibly affect the phenotype of transformed or transfected
cells, hosts, colonies or plaques. Preferred vectors are those
capable of autonomous replication and expression of the structural
gene products present in the DNA segments to which they are
operably joined.
[0145] The expression vectors of the present invention include
regulatory sequences operably joined to a nucleotide sequence
encoding one of the peptides of the invention. As used herein, the
term "regulatory sequences" means nucleotide sequences which are
necessary for, or conducive to, the transcription of a nucleotide
sequence which encodes a desired polypeptide and/or which are
necessary for or conducive to the translation of the resulting
transcript into the desired polypeptide. Regulatory sequences
include, but are not limited to, 5' sequences such as operators,
promoters and ribosome binding sequences, and 3' sequences such as
polyadenylation signals. The vectors of the invention may
optionally include 5' leader or signal sequences, 5' or 3'
sequences encoding fusion products to aid in protein purification,
and various markers which aid in the identification or selection of
transformants. The choice and design of an appropriate vector is
within the ability and discretion of one of ordinary skill in the
art. The subsequent purification of the peptides may be
accomplished by any of a variety of standard means known in the
art.
[0146] A preferred vector for screening peptides, but not
necessarily preferred for the mass production of the peptides of
the invention, is a recombinant DNA molecule containing a
nucleotide sequence that codes for and is capable of expressing a
fusion polypeptide containing, in the direction of amino- to
carboxy-terminus, (1) a prokaryotic secretion signal domain, (2) a
polypeptide of the invention, and, optionally, (3) a fusion protein
domain. The vector includes DNA regulatory sequences for expressing
the fusion polypeptide, preferably prokaryotic regulatory
sequences. Such vectors can be constructed by those with skill in
the art and have been described by Smith et al. (Science
228:1315-1317, 1985), Clackson et al. (Nature 352:624-628, 1991);
Kang et al. (in "Methods: A Companion to Methods in Enzymology:
Vol. 2", R. A. Lerner and D. R. Burton, ed. Academic Press, NY, pp
111-118, 1991); Barbas et al. (Proc. Natl. Acad. Sci. (USA)
88:7978-7982, 1991), Roberts et al. (Proc. Natl. Acad. Sci. (USA)
89:2429-2433, 1992)
[0147] A fusion polypeptide may be useful for purification of the
peptides of the invention. The fusion domain may, for example,
include a poly-His tail which allows for purification on Ni+
columns or the maltose binding protein of the commercially
available vector pMAL (New England BioLabs, Beverly, Mass.). A
currently preferred, but by no means necessary, fusion domain is a
filamentous phage membrane anchor. This domain is particularly
useful for screening phage display libraries of monoclonal
antibodies but may be of less utility for the mass production of
antibodies. The filamentous phage membrane anchor is preferably a
domain of the cpIII or cpVIII coat protein capable of associating
with the matrix of a filamentous phage particle, thereby
incorporating the fusion polypeptide onto the phage surface, to
enable solid phase binding to specific antigens or epitopes and
thereby allow enrichment and selection of the specific antibodies
or fragments encoded by the phagemid vector.
[0148] The secretion signal is a leader peptide domain of a protein
that targets the protein membrane of the host cell, such as the
periplasmic membrane of gram negative bacteria. A preferred
secretion signal for E. coli is a pelB secretion signal. The
predicted amino acid residue sequences of the secretion signal
domain from two pelB gene producing variants from Erwinia carotova
are described in Lei, et al. (Nature 381:543-546, 1988). The leader
sequence of the pelB protein has previously been used as a
secretion signal for fusion proteins (Better, et al., Science
240:1041-1043, 1988; Sastry, et al., Proc. Natl. Acad. Sci (USA)
86:5728-5732, 1989; and Mullinax, et al., Proc. Natl. Acad. Sci.
(USA) 87:8095-8099, 1990). Amino acid residue sequences for other
secretion signal polypeptide domains from E. coli useful in this
invention can be found in Oliver, In Neidhard, F. C. (ed.),
Escherichia coli and Salmonella Typhimurium, American Society for
Microbiology, Washington, D.C., 1:56-69 (1987).
[0149] To achieve high levels of gene expression in E. coli, it is
necessary to use not only strong promoters to generate large
quantities of mRNA, but also ribosome binding sites to ensure that
the mRNA is efficiently translated. In E. coli, the ribosome
binding site includes an initiation codon (AUG) and a sequence 3-9
nucleotides long located 3-11 nucleotides upstream from the
initiation codon (Shine, et al., Nature 254:34, 1975). The
sequence, AGGAGGU, which is called the Shine-Dalgarno (SD)
sequence, is complementary to the 3' end of E. coli 16S rRNA.
Binding of the ribosome to mRNA and the sequence at the 3' end of
the mRNA can be affected by several factors: (i) the degree of
complementarity between the SD sequence and 3' end of the 16S rRNA;
(ii) the spacing and possibly the DNA sequence lying between the SD
sequence and the AUG (Roberts, et al., Proc. Natl. Acad. Sci. (USA)
76:760, 1979a: Roberts, et al., Proc. Natl. Acad. Sci. (USA)
76:5596, 1979b; Guarente, et al., Science 209:1428, 1980; and
Guarente, et al., Cell 20:543, 1980). Optimization is achieved by
measuring the level of expression of genes in plasmids in which
this spacing is systematically altered. Comparison of different
mRNAs shows that there are statistically preferred sequences from
positions -20 to +13 (where the A of the AUG is position 0) (Gold,
et al., Annu. Rev. Microbiol. 35:365, 1981). Leader sequences have
been shown to influence translation dramatically (Roberts, et al.,
1979a, b supra); and (iii) the nucleotide sequence following the
AUG, which affects ribosome binding (Taniguchi, et al., J. Mol.
Biol., 118:533, 1978).
[0150] The 3' regulatory sequences define at least one termination
(stop) codon in frame with and operably joined to the heterologous
fusion polypeptide.
[0151] In preferred embodiments with a prokaryotic expression host,
the vector utilized includes a prokaryotic origin of replication or
replicon, i.e., a DNA sequence having the ability to direct
autonomous replication and maintenance of the recombinant DNA
molecule extra-chromosomally in a prokaryotic host cell, such as a
bacterial host cell, transformed therewith. Such origins of
replication are well known in the art. Preferred origins of
replication are those that are efficient in the host organism. A
preferred host cell is E. coli. For use of a vector in E. coli, a
preferred origin of replication is ColE1 found in pBR322 and a
variety of other common plasmids. Also preferred is the p15A origin
of replication found on pACYC and its derivatives. The ColE1 and
p15A replicons have been extensively utilized in molecular biology,
are available on a variety of plasmids and are described by
Sambrook. et al., Molecular Cloning: A Laboratory Manual, 2nd
edition, Cold Spring Harbor Laboratory Press, 1989).
[0152] In addition, those embodiments that include a prokaryotic
replicon preferably also include a gene whose expression confers a
selective advantage, such as drug resistance, to a bacterial host
transformed therewith. Typical bacterial drug resistance genes are
those that confer resistance to ampicillin, tetracycline,
neomycin/kanamycin or chloramphenicol. Vectors typically also
contain convenient restriction sites for insertion of translatable
DNA sequences. Exemplary vectors are the plasmids pUC18 and pUC19
and derived vectors such as pcDNAII available from Invitrogen, (San
Diego, Calif.).
[0153] When the peptide of the invention is an antibody including
both heavy chain and light chain sequences, these sequences may be
encoded on separate vectors or, more conveniently, may be expressed
by a single vector. The heavy and light chain may, after
translation or after secretion, form the heterodimeric structure of
natural antibody molecules. Such a heterodimeric antibody may or
may not be stabilized by disulfide bonds between the heavy and
light chains.
[0154] A vector for expression of heterodimeric antibodies, such as
the intact antibodies of the invention or the F(ab').sub.2, Fab or
Fv fragment antibodies of the invention, is a recombinant DNA
molecule adapted for receiving and expressing translatable first
and second DNA sequences. That is, a DNA expression vector for
expressing a heterodimeric antibody provides a system for
independently cloning (inserting) the two translatable DNA
sequences into two separate cassettes present in the vector, to
form two separate cistrons for expressing the first and second
polypeptides of a heterodimeric antibody. The DNA expression vector
for expressing two cistrons is referred to as a dicistronic
expression vector.
[0155] Preferably, the vector comprises a first cassette that
includes upstream and downstream DNA regulatory sequences operably
joined via a sequence of nucleotides adapted for directional
ligation to an insert DNA. The upstream translatable sequence
preferably encodes the secretion signal as described above. The
cassette includes DNA regulatory sequences for expressing the first
antibody polypeptide that is produced when an insert translatable
DNA sequence (insert DNA) is directionally inserted into the
cassette via the sequence of nucleotides adapted for directional
ligation.
[0156] The dicistronic expression vector also contains a second
cassette for expressing the second antibody polypeptide. The second
cassette includes a second translatable DNA sequence that
preferably encodes a secretion signal, as described above, operably
joined at its 3' terminus via a sequence of nucleotides adapted for
directional ligation to a downstream DNA sequence of the vector
that typically defines at least one stop codon in the reading frame
of the cassette. The second translatable DNA sequence is operably
joined at its 5' terminus to DNA regulatory sequences forming the
5' elements. The second cassette is capable, upon insertion of a
translatable DNA sequence (insert DNA), of expressing the second
fusion polypeptide comprising a secretion signal with a polypeptide
coded by the insert DNA.
[0157] The peptides of the present invention may also be produced
by eukaryotic cells such as CHO cells, human hybridomas,
immortalized B-lymphoblastoid cells, and the like. In this case, a
vector is constructed in which eukaryotic regulatory sequences are
operably joined to the nucleotide sequences encoding the peptide.
The design and selection of an appropriate eukaryotic vector is
within the ability and discretion of one of ordinary skill in the
art. The subsequent purification of the peptides may be
accomplished by any of a variety of standard means known in the
art.
[0158] In another embodiment, the present invention provides host
cells, both prokaryotic and eukaryotic, transformed or transfected
with, and therefore including, the vectors of the present
invention.
[0159] As used herein with respect to nucleic acids, the term
"isolated" means: (i) amplified in vitro by, for example,
polymerase chain reaction (PCR); (ii) recombinantly produced by
cloning; (iii) purified, as by cleavage and gel separation; or (iv)
synthesized by, for example, chemical synthesis. An isolated
nucleic acid is one which is readily manipulable by recombinant DNA
techniques well known in the art. Thus, a nucleotide sequence
contained in a vector in which 5' and 3' restriction sites are
known or for which polymerase chain reaction (PCR) primer sequences
have been disclosed is considered isolated but a nucleic acid
sequence existing in its native state in its natural host is not.
An isolated nucleic acid may be substantially purified, but need
not be. For example, a nucleic acid that is isolated within a
cloning or expression vector is not pure in that it may comprise
only a tiny percentage of the material in the cell in which it
resides. Such a nucleic acid is isolated, however, as the term is
used herein because it is readily manipulable by standard
techniques known to those of ordinary skill in the art.
[0160] As used herein, a coding sequence and regulatory sequences
are said to be "operably joined" when they are covalently linked in
such a way as to place the expression or transcription of the
coding sequence under the influence or control of the regulatory
sequences. If it is desired that the coding sequences be translated
into a functional protein, two DNA sequences are said to be
operably joined if induction of a promoter in the 5' regulatory
sequences results in the transcription of the coding sequence and
if the nature of the linkage between the two DNA sequences does not
(1) result in the introduction of a frame-shift mutation, (2)
interfere with the ability of the promoter region to direct the
transcription of the coding sequences, or (3) interfere with the
ability of the corresponding RNA transcript to be translated into a
protein. Thus, a promoter region would be operably joined to a
coding sequence if the promoter region were capable of effecting
transcription of that DNA sequence such that the resulting
transcript might be translated into the desired protein or
polypeptide.
[0161] The precise nature of the regulatory sequences needed for
gene expression may vary between species or cell types, but shall
in general include, as necessary, 5' non-transcribing and 5'
non-translating sequences involved with initiation of transcription
and translation respectively, such as a TATA box, capping sequence,
CAAT sequence, and the like. Especially, such 5' non-transcribing
regulatory sequences will include a promoter region which includes
a promoter sequence for transcriptional control of the operably
joined gene. Regulatory sequences may also include enhancer
sequences or upstream activator sequences, as desired.
[0162] The invention also intends to embrace the use of the
peptides described herein in in vivo and in vitro methods. In
particular, the peptides can be used in detection methods as well
as in treatment methods. The detection or diagnosis methods
provided by the invention generally involve contacting one or more
peptides of the invention with a sample in or from a subject.
Preferably, the sample is first harvested from the subject,
although in vivo detection methods are also envisioned. The sample
may include any body tissue or fluid that is suspected of harboring
the bacteria. A P. aeruginosa infection can affect any number of
tissues including eye, ear, respiratory tract (including lung),
heart (including heart valve), central nervous system, bone and
joint, gastrointestinal tract (including large bowel), urinary
tract, skin, and soft tissues. Lung or gastrointestinal lavages, or
CNS fluid can all be sampled and tested for the presence of the
bacteria.
[0163] In order to detect the bacteria, the sample is contacted
with a peptide of the invention and the level of binding of the
peptide is compared to the level of binding of the peptide to a
sample that is known to be negative for the bacteria (i.e., a
negative control). Peptides that are conjugated to a detectable
label are most useful in these assays. Methods of conjugating
peptides to detectable labels or cytotoxic agents are described in
greater detail above.
[0164] The invention also embraces methods of detecting P.
aeruginosa in or on medical equipment, surfaces, instrumentation,
and the like, in order to identify contamination of the bacteria.
These detection methods are carried out essentially in the same
manner as those described above. The items and surfaces to be
tested are either contacted directly with the peptides of the
invention, or alternatively, they are sampled and the sample is
tested for the presence of the bacteria. Sampling can include but
is not limited to swabbing, wiping, flushing, and the like.
[0165] As used herein, the term "treatment" refers to the
administration of peptides to a subject for the purpose of
achieving a medically desirable benefit. Accordingly, "treatment"
intends to embrace both "prophylactic" and "therapeutic" treatment
methods. Prophylactic treatment methods refer to treatment
administered to a subject prior to the diagnosis of a P. aeruginosa
infection or a P. aeruginosa related condition. In other words, the
subject does not present with symptoms of either a P. aeruginosa
infection or a P. aeruginosa related condition although the subject
may be at risk of either. Therapeutic treatment methods refer to
treatment administered to a subject after the diagnosis of a P.
aeruginosa infection or a P. aeruginosa related condition. In other
words, the subject has been diagnosed as having either a P.
aeruginosa infection or a P. aeruginosa related condition or
alternatively, the subject may exhibit symptoms associated with
either.
[0166] As used herein, a subject is a human, non-human primate,
cow, horse, pig, sheep, goat, dog, cat or rodent. In all
embodiments, human subjects are preferred.
[0167] When used therapeutically, an effective amount is that
amount which inhibits the P. aeruginosa infection. Such inhibition
may be measured by a partial or complete inhibition of bacterial
cell proliferation or, in some instances, partial or complete
elimination of bacterial colonies, which can generally be measured
by a reduction in number of bacteria or bacterial colonies. When
used prophylactically, an effective amount is that amount which
prevents a P. aeruginosa infection from arising. Such inhibition
may be measured by an absence of bacteria in a lung lavage from,
for example, subjects having cystic fibrosis or subjects at risk of
developing cystic fibrosis. Generally, a therapeutically effective
amount may vary with the subject's age, condition, and sex, as well
as the extent of the disease in the subject and can be determined
by one of skill in the art. The dosage may be adjusted by the
individual physician in the event of any complication.
[0168] The present invention also includes a method for treating a
P. aeruginosa related disorder. A "P. aeruginosa related disorder"
as used herein is any disorder associated with the presence of P.
aeruginosa infection. These disorders include cystic fibrosis,
ulcerative keratitis, pneumonia, bacteremia, organ and tissue
infection such as kidney, bladder, liver, brain, skin, muscle,
lymph node or sinus infection. The method involves the step of
administering a peptide of the invention to a subject having such a
disorder in an amount effective to inhibit the disorder. The
disorder is "inhibited" if symptoms associated with the disorder
are lessened. In some instances, this amount may be similar to that
required to inhibit a P. aeruginosa infection in the subject.
[0169] An effective amount typically will vary from about 0.01
mg/kg to about 1000 mg/kg, more typically from about 0.1 mg/kg to
about 200 mg/kg, and often from about 0.2 mg/kg to about 20 mg/kg,
in one or more dose administrations daily, for one or several days
(depending of course of the mode of administration and the factors
discussed above).
[0170] One of skill in the art can determine what an effective
amount of a peptide is by screening the ability of the peptide to
bind to P. aeruginosa MEP and optionally to enhance opsonization
and phagocytosis in vitro. Exemplary assays for measuring the
ability of a peptide of the invention to bind to P. aeruginosa MEP
and optionally to enhance opsonization and phagocytosis are
provided in the Examples and have been discussed above.
[0171] According to the methods of the invention, the peptide may
be administered in a pharmaceutical composition. In general, a
pharmaceutical composition comprises the peptide of the invention
and a pharmaceutically-acceptable carrier.
Pharmaceutically-acceptable carriers for peptides, monoclonal
antibodies, and antibody fragments are well-known to those of
ordinary skill in the art. As used herein, a
pharmaceutically-acceptable carrier means a non-toxic material that
does not interfere with the effectiveness of the biological
activity of the active ingredients, i.e., the ability of the
peptide to bind to P. aeruginosa MEP and optionally to enhance
opsonization and phagocytosis.
[0172] Pharmaceutically acceptable carriers include diluents,
fillers, salts, buffers, stabilizers, solubilizers and other
materials which are well-known in the art. Exemplary
pharmaceutically acceptable carriers for peptides in particular are
described in U.S. Pat. No. 5,211,657. Such preparations may
routinely contain salt, buffering agents, preservatives, compatible
carriers, and optionally other therapeutic agents. When used in
medicine, the salts should be pharmaceutically acceptable, but
non-pharmaceutically acceptable salts may conveniently be used to
prepare pharmaceutically-acceptable salts thereof and are not
excluded from the scope of the invention. Such pharmacologically
and pharmaceutically-acceptable salts include, but are not limited
to, those prepared from the following acids: hydrochloric,
hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic,
salicylic, citric, formic, malonic, succinic, and the like. Also,
pharmaceutically-acceptable salts can be prepared as alkaline metal
or alkaline earth salts, such as sodium, potassium or calcium
salts.
[0173] The peptides of the invention may be formulated into
preparations in solid, semi-solid, liquid or gaseous forms such as
tablets, capsules, powders, granules, ointments, solutions,
depositories, inhalants and injections, and usual ways for oral,
parenteral or surgical administration. The invention also embraces
pharmaceutical compositions which are formulated for local
administration, such as by implants.
[0174] A variety of administration routes are available. The
methods of the invention, generally speaking, may be practiced
using any mode of administration that is medically acceptable,
meaning any mode that produces effective levels of the active
compounds without causing clinically unacceptable adverse effects.
According to the methods of the invention the peptides can be
administered by injection, by gradual infusion over time or by any
other medically acceptable mode. Such modes of administration
include oral, rectal, topical, nasal, interdermal, or parenteral
routes. The term "parenteral" includes subcutaneous, intravenous,
intramuscular, or infusion. Intravenous or intramuscular routes are
not particularly suitable for long-term therapy and prophylaxis.
They could, however, be preferred in emergency situations. Oral
administration may be preferred for prophylactic treatment because
of the convenience to the patient as well as the dosing schedule.
Compositions suitable for oral administration may be presented as
discrete units, such as capsules, tablets, lozenges, each
containing a predetermined amount of the active agent. Other
compositions include suspensions in aqueous liquids or non-aqueous
liquids such as a syrup, elixir or an emulsion.
[0175] When the compounds described herein (including peptide and
non-peptide varieties) are used therapeutically, in certain
embodiments a desirable route of administration may be by pulmonary
aerosol. Techniques for preparing aerosol delivery systems
containing compounds are well known to those of skill in the art.
Generally, such systems should utilize components which will not
significantly impair the biological properties of the peptides
(see, for example, Sciarra and Cutie, "Aerosols," in Remington's
Pharmaceutical Sciences, 18th edition, 1990, pp 1694-1712;
incorporated by reference). Those of skill in the art can readily
determine the various parameters and conditions for producing
aerosols without resort to undue experimentation.
[0176] The methods of the invention also encompass the step of
administering the peptides of the invention in conjunction with
conventional therapies for treating the underlying bacterial
infection. For example, the method of the invention may be
practiced simultaneously with a conventional treatment, such as for
example antibiotic therapy. In some embodiments, the peptides may
be administered substantially simultaneously with the conventional
treatment. By substantially simultaneously, it is meant that a
peptide of the invention is administered to a subject close enough
in time with the administration of the conventional treatment
(e.g., antibiotic), whereby the two compounds may exert an additive
or even synergistic effect. In some instances, the peptide and the
agent of the conventional treatment are conjugated to each other.
In others, the compounds are physically separate.
[0177] The peptides of the invention may be administered directly
to a tissue. Preferably, the tissue is one in which the bacterial
infection exists, such as for example, the lungs in cystic fibrosis
patients. Alternatively, the tissue is one in which the infection
is likely to arise. Direct tissue administration may be achieved by
direct injection. The peptides may be administered once, or
alternatively they may be administered in a plurality of
administrations. If administered multiple times, the peptides may
be administered via different routes. For example, the first (or
the first few) administrations may be made directly into the
affected tissue while later administrations may be systemic.
[0178] Preparations for parenteral administration include sterile
aqueous or non-aqueous solutions, suspensions, and emulsions.
Examples of non-aqueous solvents are propylene glycol, polyethylene
glycol, vegetable oils such as olive oil, and injectable organic
esters such as ethyl oleate. Aqueous carriers include water,
alcoholic/aqueous solutions, emulsions or suspensions, including
saline and buffered media. Parenteral vehicles include sodium
chloride solution, Ringer's dextrose, dextrose and sodium chloride,
lactated Ringer's, or fixed oils. Intravenous vehicles include
fluid and nutrient replenishers, electrolyte replenishers (such as
those based on Ringer's dextrose), and the like. Preservatives and
other additives may also be present such as, for example,
antimicrobials, anti-oxidants, chelating agents, and inert gases
and the like. Lower doses will result from other forms of
administration, such as intravenous administration. In the event
that a response in a subject is insufficient at the initial doses
applied, higher doses (or effectively higher doses by a different,
more localized delivery route) may be employed to the extent that
patient tolerance permits. Multiple doses per day are contemplated
to achieve appropriate systemic levels of compounds.
[0179] In yet other embodiments, the preferred vehicle is a
biocompatible microparticle or implant that is suitable for
implantation into the mammalian recipient. Exemplary bioerodible
implants that are useful in accordance with this method are
described in PCT International Application No. PCT/US/03307
(Publication No. WO 95/24929, entitled "Polymeric Gene Delivery
System", claiming priority to U.S. patent application Ser. No.
213,668, filed Mar. 15, 1994). PCT/US/0307 describes a
biocompatible, preferably biodegradable polymeric matrix for
containing a biological macromolecule. The polymeric matrix may be
used to achieve sustained release of the agent in a subject. In
accordance with one aspect of the instant invention, the agent
described herein may be encapsulated or dispersed within the
biocompatible, preferably biodegradable polymeric matrix disclosed
in PCT/US/03307. The polymeric matrix preferably is in the form of
a microparticle such as a microsphere (wherein the agent is
dispersed throughout a solid polymeric matrix) or a microcapsule
(wherein the agent is stored in the core of a polymeric shell).
Other forms of the polymeric matrix for containing the agent
include films, coatings, gels, implants, and stents. The size and
composition of the polymeric matrix device is selected to result in
favorable release kinetics in the tissue into which the matrix
device is implanted. The size of the polymeric matrix device
further is selected according to the method of delivery which is to
be used, typically injection into a tissue or administration of a
suspension by aerosol into the nasal and/or pulmonary areas. The
polymeric matrix composition can be selected to have both favorable
degradation rates and also to be formed of a material which is
bioadhesive, to further increase the effectiveness of transfer when
the device is administered to a vascular, pulmonary, or other
surface. The matrix composition also can be selected not to
degrade, but rather, to release by diffusion over an extended
period of time.
[0180] Both non-biodegradable and biodegradable polymeric matrices
can be used to deliver the agents of the invention to the subject.
Biodegradable matrices are preferred. Such polymers may be natural
or synthetic polymers. Synthetic polymers are preferred. The
polymer is selected based on the period of time over which release
is desired, generally in the order of a few hours to a year or
longer. Typically, release over a period ranging from between a few
hours and three to twelve months is most desirable. The polymer
optionally is in the form of a hydrogel that can absorb up to about
90% of its weight in water and further, optionally is cross-linked
with multivalent ions or other polymers.
[0181] In general, the agents of the invention may be delivered
using the bioerodible implant by way of diffusion, or more
preferably, by degradation of the polymeric matrix. Exemplary
synthetic polymers which can be used to form the biodegradable
delivery system include: polyamides, polycarbonates, polyalkylenes,
polyalkylene glycols, polyalkylene oxides, polyalkylene
terepthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl
esters, poly-vinyl halides, polyvinylpyrrolidone, polyglycolides,
polysiloxanes, polyurethanes and co-polymers thereof, alkyl
cellulose, hydroxyalkyl celluloses, cellulose ethers, cellulose
esters, nitro celluloses, polymers of acrylic and methacrylic
esters, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose,
hydroxy-propyl methyl cellulose, hydroxybutyl methyl cellulose,
cellulose acetate, cellulose propionate, cellulose acetate
butyrate, cellulose acetate phthalate, carboxylethyl cellulose,
cellulose triacetate, cellulose sulphate sodium salt, poly(methyl
methacrylate), poly(ethyl methacrylate), poly(butylmethacrylate),
poly(isobutyl methacrylate), poly(hexylmethacrylate), poly(isodecyl
methacrylate), poly(lauryl methacrylate), poly(phenyl
methacrylate), poly(methyl acrylate), poly(isopropyl acrylate),
poly(isobutyl acrylate), poly(octadecyl acrylate), polyethylene,
polypropylene, poly(ethylene glycol), poly(ethylene oxide),
poly(ethylene terephthalate), poly(vinyl alcohols), polyvinyl
acetate, poly vinyl chloride, polystyrene and
polyvinylpyrrolidone.
[0182] Examples of non-biodegradable polymers include ethylene
vinyl acetate, poly(meth)acrylic acid, polyamides, copolymers and
mixtures thereof.
[0183] Examples of biodegradable polymers include synthetic
polymers such as polymers of lactic acid and glycolic acid,
polyanhydrides, poly(ortho)esters, polyurethanes, poly(butic acid),
poly(valeric acid), and poly(lactide-cocaprolactone), and natural
polymers such as alginate and other polysaccharides including
dextran and cellulose, collagen, chemical derivatives thereof
(substitutions, additions of chemical groups, for example, alkyl,
alkylene, hydroxylations, oxidations, and other modifications
routinely made by those skilled in the art), albumin and other
hydrophilic proteins, zein and other prolamines and hydrophobic
proteins, copolymers and mixtures thereof. In general, these
materials degrade either by. enzymatic hydrolysis or exposure to
water in vivo, by surface or bulk erosion.
[0184] Bioadhesive polymers of particular interest include
bioerodible hydrogels described by H. S. Sawhney, C. P. Pathak and
J. A. Hubell in Macromolecules, 1993, 26, 581-587, the teachings of
which are incorporated herein, polyhyaluronic acids, casein,
gelatin, glutin, polyanhydrides, polyacrylic acid, alginate,
chitosan, poly(methyl methacrylates), poly(ethyl methacrylates),
poly(butylmethacrylate), poly(isobutyl methacrylate),
poly(hexylmethacrylate), poly(isodecyl methacrylate), poly(lauryl
methacrylate), poly(phenyl methacrylate), poly(methyl acrylate),
poly(isopropyl acrylate), poly(isobutyl acrylate), and
poly(octadecyl acrylate).
[0185] Other delivery systems can include time-release, delayed
release or sustained release delivery systems. Such systems can
avoid repeated administrations of the peptide, increasing
convenience to the subject and the physician. Many types of release
delivery systems are available and known to those of ordinary skill
in the art. They include polymer base systems such as
poly(lactide-glycolide), copolyoxalates, polycaprolactones,
polyesteramides, polyorthoesters, polyhydroxybutyric acid, and
polyanhydrides. Microcapsules of the foregoing polymers containing
drugs are described in, for example, U.S. Pat. No. 5,075,109.
Delivery systems also include non-polymer systems that are: lipids
including sterols such as cholesterol, cholesterol esters and fatty
acids or neutral fats such as mono- di- and tri-glycerides;
hydrogel release systems; silastic systems; peptide based systems;
wax coatings; compressed tablets using conventional binders and
excipients; partially fused implants; and the like. Specific
examples include, but are not limited to: (a) erosional systems in
which the platelet reducing agent is contained in a form within a
matrix such as those described in U.S. Pat. Nos. 4,452,775,
4,675,189, and 5,736,152 and (b) diffusional systems in which an
active component permeates at a controlled rate from a polymer such
as described in U.S. Pat. Nos. 3,854,480, 5,133,974 and 5,407,686.
In addition, pump-based hardware delivery systems can be used, some
of which are adapted for implantation.
[0186] Use of a long-term sustained release implant may be
particularly suitable for prophylactic treatment of subjects at
risk of developing a P. aeruginosa infection. Long-term release, as
used herein, means that the implant is constructed and arranged to
delivery therapeutic levels of the active ingredient for at least
30 days, and preferably 60 days. Long-term sustained release
implants are well-known to those of ordinary skill in the art and
include some of the release systems described above.
[0187] The following examples are provided to illustrate specific
instances of the practice of the present invention and are not
intended to limit the scope of the invention. As will be apparent
to one of ordinary skill in the art, the present invention will
find application in a variety of compositions and methods.
EXAMPLES
Example 1
Materials and Methods
[0188] Immunization of Patients with MEP
[0189] Culture of P. aeruginosa, purification of MEP, and
immunization of subjects with MEP has been described before in U.S.
Pat. No. 4,578,458, the entire contents of which are incorporated
herein by reference. Briefly, subjects are preferably immunized
with purified MEP harvested from P. aeruginosa 2192 isolates (ATCC
No. 39324). Although P. aeruginosa strain 2192 is preferred, new
strains that produce a polysaccharide having essentially the same
antigenic determinants as present in P. aeruginosa 2192 may also be
used. P. aeruginosa can be maintained in liquid basal medium
containing essential nutrients and ingredients (e.g., Mian's
Minimal Medium, Trypticase Soy Broth and deoxycholate citrate agar,
preferably supplemented with divalent cations such as magnesium).
Methods of bacterial culture are known in the art. MEP is purified
from Mian's minimal medium, followed by precipitation of MEP with
alcohol. The precipitate is then digested with DNase and RNase,
followed by separation on a Sephacel S-300 column, precipitation
and lyophilization. The material is treated with 1% acetic acid at
95.degree. C. for 1-3 hours, cooled, and then the precipitate is
removed by centrifugation and the supernate is dialyzed and
lyophilized. This procedure results in greater than 99% purity. For
administration to a subject, the lyophilized precipitate is
reconstituted in a pharmaceutically acceptable carrier. The amount
of MEP administered corresponds to that amount required to elicit
antibody formation at a concentration at least 4 times greater than
that which existed prior to administration. Generally, this amount
is 10-500 .mu.g/dose.
[0190] Harvest of B Cells Transformation with EBV and Screening
Assays
[0191] Human blood is collected from subjects seven days after
having been administered MEP. Peripheral blood mononuclear cells
are isolated from the blood by ficoll-hypaque sedimentation and
transformed with EBV as described by Posner et al. (Autoimmunity,
8:149-158, 1990). Transformed B cells are screened for their
ability to recognize and bind to P. aeruginosa colonies in vitro
using ELISA. Transformed B cells secreting antibody are fused with
the immortalized cell line fusion partner HMMA 2.5 as described by
Posner et al. (Hybridoma, 6:611-625, 1987).
[0192] Clones are screened for the ability to recognize and bind to
P. aeruginosa colonies in vitro using ELISA. ELISA plates are
coated with 10 .mu.g MEP per ml of 0.04 M phosphate buffer, pH 7.4
for 2 hours at 37.degree. C. After washing, 1% skim milk is added
for 1 hour at 37.degree. C. following which plates are washed
again. Supernatants are incubated on the plates for 1 hour at
37.degree. C. After washing with PBS, horseradish peroxidase
conjugated antibody goat anti-human IgG and goat anti-human IgA are
added for 1 hour at 37.degree. C. Positive wells are selected by
color change upon adding the substrate o-phenylediamine.
[0193] Cloning of Variable Regions; Isotype Switching
[0194] MEP specific immortalized fusion B cell clones are then
further analyzed in order to derive the sequences of MEP specific
antibodies. RNA is isolated from each clone separately, and cDNA is
subsequently prepared. Human Ig light chain variable region DNA was
amplified from the cDNA by the polymerase chain reaction (PCR)
using a set of DNA primers with homology to human light chain
signal sequences at the 5' end and human light chain C region at
the 3' end. This amplified DNA fragment was inserted directly into
an expression plasmid (TCAE 5.3) in front of the human .kappa.
light chain constant domain and the entire construct was sequenced.
Similarly, a human Ig heavy chain variable region DNA was amplified
from the cDNA using PCR and a set of primers with homology to the
human heavy chain signal sequence at the 5' end and human heavy
chain CH.sub.1 region at the 3' end. This latter amplified DNA
fragment was inserted into the TCAE 5.3 expression plasmid in front
of the human IgG1 heavy chain constant domain and the entire
construct was sequenced. TCAE 5.3 is a human Ig expression vector
that has been described by Reff et al. Blood 83:435-445, 1994. It
contains human IgG1 heavy chain and human kappa light chain
constant region genes on the same plasmid.
[0195] The resultant expression vectors were introduced into a
Chinese Hamster Ovary (CHO) cell line DGH44 (obtained from Dr.
Larry Chasin, Columbia University, New York) either by
DNA-liposome-mediated transfection or by electroporation, as
described by Preston et al. Infection and Immunity 66:4137-4142,
1998, and by Reff et al. Blood 83:435-445, 1994. The supernatant in
which the transfected CHO cell line was grown was tested for
antibody production using ELISA. Antibodies were purified from
culture supernatant using protein G affinity chromatography (for
IgG isotypes) and lectin Jacalin affinity chromatography (for IgA
isotype).
Results:
[0196] Three clones of transformed human B cells from an individual
immunized with a MEP vaccine were obtained. These clones were
identified on the basis of their ability to produce an antibody
that bound to the purified MEP antigen. All three were of the
IgA/lambda isotype. They were designated F428, F429 and F431.
[0197] The nucleotide sequence encoding the variable regions of the
light and heavy chains of each of these three clones was
determined. From the three clones, two different heavy chain
sequences and two different light chain sequences were identified,
in the following combinations: TABLE-US-00003 Clone Heavy Chain
Light Chain F428 A 1 F429 A 2 F431 B 1 COMB B 2
[0198] A fourth antibody molecule was constructed using the B heavy
chain and second light chain to produce an antibody labeled "COMB"
(for combination). Thus recombinant antibody molecules containing
all four possible pairs of heavy and light chains identified among
the original three clones have been constructed and expressed.
[0199] The following data contain nucleotide and amino acid
sequence information for the two different heavy chains and two
different light chains.
[0200] Nucleotide sequence of the variable region of the heavy
chain of human monoclonal antibodies F428 and F429 specific to the
P. aeruginosa MEP antigen starting with the first nucleotide for
the initial amino acid in the first framework region (FAR) and
ending with the last nucleotide for the end of the variable region
(i.e., SEQ ID NO: 1): TABLE-US-00004
CAGCTGCAGCTGCAGGAGTCGGGCCCCGGACTGGTGAAGCCTACGGAGAC
CCTGTCCCTCACCTGCACTGTCTCTGGTGGCCCCATCACCTATATTAATT
ACTACTGGGGCTGGGTCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATT
GGGAGTATCCATTATGATGGGAGCACCTTCTACAACCCGTCCCTCAAGAG
TCGCGTCACCATATCAGGAGACACGTCCAAGAGCGAGTTCTCTGTGAAGC
TGAGTTCTGTGACCGCCGCGGACACGGCCGTCTATTACTGTGCGAGAACG
TATTACGATGCTTCGGGGAGCCCTTACTTTGACCACTGGGGCCAGGGAAC
CCTGGTCACCGTCTCCTCA
[0201] Nucleotide sequence of the framework region 1 (FR1) of the
heavy chain of human monoclonal antibodies F428 and F429 (i.e., SEQ
ID NO:33): TABLE-US-00005
CAGCTGCAGCTGCAGGAGTCGGGCCCCGGACTGGTGAAGCCTACGGAGAC
CCTGTCCCTCACCTGCACTGTCTCTGGTGGCCCCATCACC.
[0202] Nucleotide sequence of CDR1 of the heavy chain of human
monoclonal antibodies F428 and F429 (i.e., SEQ ID NO:9):
TABLE-US-00006 TATATTAATTACTACTGGGGC.
[0203] Nucleotide sequence of the FR2 of the heavy chain of human
monoclonal antibodies F428 and F429 (i.e., SEQ ID NO:34):
TABLE-US-00007 TGGGTCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGG.
[0204] Nucleotide sequence of CDR2 of the heavy chain of human
monoclonal antibodies F428 and F429 (i.e., SEQ ID NO:10):
TABLE-US-00008
AGTATCCATTATGATGGGAGCACCTTCTACAACCCGTCCCTCAAGAGT.
[0205] Nucleotide sequence of the FR3 of the heavy chain of human
monoclonal antibodies F428 and F429 (i.e., SEQ ID NO:35):
TABLE-US-00009 CGCGTCACCATATCAGGAGACACGTCCAAGAGCGAGTTCTCTGTGAAGCT
GAGTTCTGTGACCGCCGCGGACACGGCCGTCTATTACTGTGCGAGA.
[0206] Nucleotide sequence of CDR3 of the heavy chain of human
monoclonal antibodies s F428 and F429 (i.e., SEQ ID NO:11):
TABLE-US-00010 ACGTATTACGATGCTTCGGGGAGCCCTTACTTTGACCAC.
[0207] Nucleotide sequence of the FR4 of the heavy chain of human
monoclonal antibodies F428 and F429 (i.e., SEQ ID NO:36):
TABLE-US-00011 TGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA.
[0208] Single amino acid sequence of the variable region of the
heavy chain of human monoclonal antibodies F428 and F429 specific
to the P. aeruginosa MEP antigen (i.e., SEQ ID NO:5):
TABLE-US-00012 QLQLQESGPGLVKPTETLSLTCTVSGGPITYINYYWGWVRQPPGKGLEWI
GSIHYDGSTFYNPSLKSRVTISGDTSKSEFSVKLSSVTAADTAVYYCART
YYDASGSPYFDHWGQGTLVTVSS
[0209] Single amino acid sequence of FR1 of the heavy chain of
human monoclonal antibodies F428 and F429 specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:49): TABLE-US-00013
QLQLQESGPGLVKPTETLSLTCTVSGGPIT.
[0210] Single amino acid sequence of CDR1 of the heavy chain of
human monoclonal antibodies F428 and F429 specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:21): TABLE-US-00014
YINYYWG.
[0211] Single amino acid sequence of FR2 of the heavy chain of
human monoclonal antibodies F428 and F429 specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:50): TABLE-US-00015
WVRQPPGKGLEWIG.
[0212] Single amino acid sequence of CDR2 of the heavy chain of
human monoclonal antibodies F428 and F429 specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:22): TABLE-US-00016
SIHYDGSTFYNPSLKS.
[0213] Single amino acid sequence of FR3 of the heavy chain of
human monoclonal antibodies F428 and F429 specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:51): TABLE-US-00017
RVTISGDTSKSEFSVKLSSVTAADTAVYYCAR.
[0214] Single amino acid sequence of CDR2 of the heavy chain of
human monoclonal antibodies F428 and F429 specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:23): TABLE-US-00018
TYYDASGSPYFDH.
[0215] Single amino acid sequence of FR4 of the heavy chain of
human monoclonal antibodies F428 and F429 specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:52): TABLE-US-00019
WGQGTLVTVSS.
[0216] Nucleotide sequence of the variable region of the light
chain of human monoclonal antibodies F428 and F431 specific to the
P. aeruginosa MEP antigen (SEQ ID NO:2): TABLE-US-00020
CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAG
GGTCACCATCTCCTGCTCTGGAAGCAGCTCCAACCTTGGGAACAATTTTG
TATCCTGGTACCAGCAACTCCCAGGAGCAGCCCCCCGGCTCCTCATTTAT
GACAATGATAAGCGACCCTCAGGGATTCCTGACCGATTCTCTGGCTCCAA
GTCTGGCACGTCAGCCACCCTGGGCATCACCGGGCTCCAGACTGGGGACG
AGGCCGATTATTACTGCGGAACATGGGATAGCAGCCTGACTGCTTATGTC
TTCGGAAGTGGGACCAAGGTCACCGTCCTA.
[0217] Nucleotide sequence of FR1 of the heavy chain of human
monoclonal antibodies F428 and F431 (i.e., SEQ ID NO:37):
TABLE-US-00021 CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAG
GGTCACCATCTCCTGC.
[0218] Nucleotide sequence of CDR1 of the heavy chain of human
monoclonal antibodies F428 and F431 (i.e., SEQ ID NO:12):
TABLE-US-00022 TCTGGAAGCAGCTCCAACCTTGGGAACAATTTTGTATCC.
[0219] Nucleotide sequence of the FR2 of the heavy chain of human
monoclonal antibodies F428 and F431 (i.e., SEQ ID NO:38):
TABLE-US-00023 TGGTACCAGCAACTCCCAGGAGCAGCCCCCCGGCTCCTCATTTAT.
[0220] Nucleotide sequence of CDR2 of the heavy chain of human
monoclonal antibodies F428 and F431 (i.e., SEQ ID NO:13):
TABLE-US-00024 GACAATGATAAGCGACCCTCA.
[0221] Nucleotide sequence of the FR3 of the heavy chain of human
monoclonal antibodies F428 and F431 (i.e., SEQ ID NO:39):
TABLE-US-00025 GGGATTCCTGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCT
GGGCATCACCGGGCTCCAG ACTGGGGACGAGGCCGATTATTACTGC.
[0222] Nucleotide sequence of CDR3 of the heavy chain of human
monoclonal antibodies F428 and F431 (i.e., SEQ ID NO:14):
TABLE-US-00026 GGAACATGGGATAGCAGCCTGACTGCTTATGTC.
[0223] Nucleotide sequence of the FR4 of the heavy chain of human
monoclonal antibodies F428 and F431 (i.e., SEQ ID NO:40):
TABLE-US-00027 TTCGGAAGTGGGACCAAGGTCACCGTCCTA.
[0224] Single amino acid sequence of the variable region of the
heavy chain of human monoclonal antibodies F428 and F431 specific
to the P. aeruginosa MEP antigen (i.e., SEQ ID NO:6):
TABLE-US-00028 QSVLTQPPSVSAAPGQRVTISCSGSSSNLGNNFVSWYQQLPGAAPRLLIY
DNDKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLTAYV FGSGTKVTV
[0225] Single amino acid sequence of FR1 of the heavy chain of
human monoclonal antibodies F428 and F431 specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:53): TABLE-US-00029
QSVLTQPPSVSAAPGQRVTISC.
[0226] Single amino acid sequence of CDR1 of the heavy chain of
human monoclonal antibodies F428 and F431 specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:24): TABLE-US-00030
SGSSSNLGNNFVS.
[0227] Single amino acid sequence of FR2 of the heavy chain of
human monoclonal antibodies F428 and F431 specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:54): TABLE-US-00031
WYQQLPGAAPRLLIY.
[0228] Single amino acid sequence of CDR2 of the heavy chain of
human monoclonal antibodies F428 and F431 specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:25): TABLE-US-00032
DNDKRPS.
[0229] Single amino acid sequence of FR3 of the heavy chain of
human monoclonal antibodies F428 and F431 specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:55): TABLE-US-00033
GIPDRFSGSKSGTSATLGITGLQTGDEADYYC.
[0230] Single amino acid sequence of CDR3 of the heavy chain of
human monoclonal antibodies F428 and F431 specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:26): TABLE-US-00034
GTWDSSLTAYV.
[0231] Single amino acid sequence of FR4 of the light chain of
human monoclonal antibodies F428 and F431 specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:56): TABLE-US-00035
FGSGTKVTV.
[0232] Nucleotide sequence of the variable region of the light
chain of human monoclonal antibodies F429 and COMB specific to the
P. aeruginosa MEP antigen (SEQ ID NO:3): TABLE-US-00036
CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAA
GGTCTCCATCTCCTGCTCTGGAAGCAGCTCCAACATTGGGAATAATTATG
TATCCTGGTACCAGCAGCTCCCAGGAACAGCCCCCAATCTCCTCATTTAT
GACAATAATAAGCGACCCTCAGGGATTCCGGACCGATTCTCTGGCTCCAA
GTCTGGCACGTCAGCCACCCTGGACATCACCGGACTCCAGAGTGGGGACG
AGGCCGATTATTACTGCGGAACATGGGATAGCAGCCTGAGTACTTGGGTG
TTCGGCGGAGGGACCAAACTGACCGTCCTA.
[0233] Nucleotide sequence of FR1 of the light chain of human
monoclonal antibodies F429 and COMB (i.e., SEQ ID NO:41):
TABLE-US-00037 CACTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAA
GGTCTCCATCTCCTGC.
[0234] Nucleotide sequence of CDR1 of the light chain of human
monoclonal antibodies F429 and COMB (i.e., SEQ ID NO:15):
TABLE-US-00038 TCTGGAAGCAGCTCCAACATTGGGAATAATTATGTATCC.
[0235] Nucleotide sequence of the FR2 of the light chain of human
monoclonal antibodies F429 and COMB (i.e., SEQ ID NO:42):
TABLE-US-00039 TGGTACCAGCAGCTCCCAGGAACAGCCCCCAATCTCCTCATTTAT.
[0236] Nucleotide sequence of CDR2 of the light chain of human
monoclonal antibodies F429 and COMB (i.e., SEQ ID NO:16):
TABLE-US-00040 GACAATAATAAGCGACCCTCA.
[0237] Nucleotide sequence of the FR3 of the light chain of human
monoclonal antibodies F429 and COMB (i.e., SEQ ID NO:43):
TABLE-US-00041 GGGATTCCGGACCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCT
GGACATCACCGGACTCCAGAGTGGGGACGAGGCCGATTATTACTGC.
[0238] Nucleotide sequence of CDR3 of the light chain of human
monoclonal antibodies F429 and COMB (i.e., SEQ ID NO:17):
TABLE-US-00042 GGAACATGGGATAGCAGCCTGAGTACTTGGGTG.
[0239] Nucleotide sequence of the FR4 of the light chain of human
monoclonal antibodies F429 and COMB (i.e., SEQ ID NO:44):
TABLE-US-00043 TTCGGCGGAGGGACCAAACTGACCGTCCTA.
[0240] Single amino acid sequence of the variable region of the
light chain of human monoclonal antibodies F429 and COMB specific
to the P. aeruginosa MEP antigen (i.e., SEQ ID NO:7):
TABLE-US-00044 QSVLTQPPSVSAAPGQKVSISCSGSSSNIGNNYVSWYQQLPGTAPNLLIY
DNNKRPSGIPDRFSGSKSGTSATLDITGLQSGDEADYYCGTWDSSLSTWV FGGGTKLTVL.
[0241] Single amino acid sequence of FR1 of the light chain of
human monoclonal antibodies F429 and COMB specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:57): TABLE-US-00045
QSVLTQPPSVSAAPGQKVSISC.
[0242] Single amino acid sequence of CDR1 of the light chain of
human monoclonal antibodies F429 and COMB specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:27): TABLE-US-00046
SGSSSNIGNNYVS.
[0243] Single amino acid sequence of FR2 of the light chain of
human monoclonal antibodies F429 and COMB specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:58): TABLE-US-00047
WYQQLPGTAPNLLIY.
[0244] Single amino acid sequence of CDR2 of the light chain of
human monoclonal antibodies F429 and COMB specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:28): TABLE-US-00048
DNNKRPS.
[0245] Single amino acid sequence of FR3 of the light chain of
human monoclonal antibodies F429 and COMB specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:59): TABLE-US-00049
GIPDRFSGSKSGTSATLDITGLQSGDEADYYC.
[0246] Single amino acid sequence of CDR3 of the light chain of
human monoclonal antibodies F429 and COMB specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:29): TABLE-US-00050
GTWDSSLSTWV.
[0247] Single amino acid sequence of FR4 of the light chain of
human monoclonal antibodies F429 and COMB specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:60): TABLE-US-00051
FGGGTKLTVL.
[0248] Nucleotide sequence of the variable region of the heavy
chain of human monoclonal antibodies F431 and COMB specific to the
P. aeruginosa MEP antigen (SEQ ID NO:4): TABLE-US-00052
CAGCTGCACCTGCAGGAGTCGGGCCCAGGACTAGTGAAGCCTTCGGAGAC
CCTGTCCCTCACGTGCACTGTCTCTGGTGGCCCCATCACCAGTAATAATT
ACTACTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATT
GGGACTATCTCTTATAATGGGTACACCTACTACATCCCGTCCCTCAGGGG
TCGAGTCACCATATCCGGAGACACGTCCAAGAACCAGTTCTCCCTGAGGG
TGAACTCTGTGACCGCCGCAGACACGGCTATGTATTACTGTGCGAGACAT
GACTATAGCATGTCGTCCGGACTTACTGACAACTGGTTCGACCCCTGGGG
CCAGGGAACCCTGGTCACCGTCTCCTCA.
[0249] Nucleotide sequence of FR1 of the heavy chain of human
monoclonal antibodies F431 and COMB (i.e., SEQ ID NO:45):
TABLE-US-00053 CAGCTGCACCTGCAGGAGTCGGGCCCAGGACTAGTGAAGCCTTCGGAGAC
CCTGTCCCTCACGTGCACTGTCTCTGGTGGCCCCATCACC.
[0250] Nucleotide sequence of CDR1 of the heavy chain of human
monoclonal antibodies F431 and COMB (i.e., SEQ ID NO:18):
TABLE-US-00054 AGTAATAATTACTACTGGGGC.
[0251] Nucleotide sequence of the FR2 of the heavy chain of human
monoclonal antibodies F431 and COMB (i.e., SEQ ID NO:46):
TABLE-US-00055 TGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGG.
[0252] Nucleotide sequence of CDR2 of the heavy chain of human
monoclonal antibodies F431 and COMB (i.e., SEQ ID NO:19):
TABLE-US-00056
ACTATCTCTTATAATGGGTACACCTACTACATCCCGTCCCTCAGGGGT.
[0253] Nucleotide sequence of the FR3 of the heavy chain of human
monoclonal antibodies F431 and COMB (i.e., SEQ ID NO:47):
TABLE-US-00057 CGAGTCACCATATCCGGAGACACGTCCAAGAACCAGTTCTCCCTGAGGGT
GAACTCTGTGACCGCCGCAGACACGGCTATGTATTACTGTGCGAG.
[0254] Nucleotide sequence of CDR3 of the heavy chain of human
monoclonal antibodies F431 and COMB (i.e., SEQ ID NO:20):
TABLE-US-00058
CATGACTATAGCATGTCGTCCGGACTTACTGACAACTGGTTCGACCCC.
[0255] Nucleotide sequence of the FR4 of the heavy chain of human
monoclonal antibodies F431 and COMB (i.e., SEQ ID NO:48):
TABLE-US-00059 TGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA.
[0256] Single amino acid sequence of the variable region of the
heavy chain of human monoclonal antibodies F431 and COMB specific
to the P. aeruginosa MEP antigen (i.e., SEQ ID NO:8):
TABLE-US-00060 QLHLQESGPGLVKPSETLSLTCTVSGGPITSNNYYWGWIRQPPGKGLEWI
GTISYNGYTYYIPSLRGRVTISGDTSKNQFSLRVNSVTAADTAMYYCARH
DYSMSSGLTDNWFDPWGQGTLVTVSS.
[0257] Single amino acid sequence of FR1 of the heavy chain of
human monoclonal antibodies F431 and COMB specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:61): TABLE-US-00061
QLHLQESGPGLVKPSETLSLTCTVSGGPIT.
[0258] Single amino acid sequence of CDR1 of the heavy chain of
human monoclonal antibodies F431 and COMB specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:30): TABLE-US-00062
SNNYYWG.
[0259] Single amino acid sequence of FR2 of the heavy chain of
human monoclonal antibodies F431 and COMB specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:62): TABLE-US-00063
WIRQPPGKGLEWIG.
[0260] Single amino acid sequence of CDR2 of the heavy chain of
human monoclonal antibodies F431 and COMB specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:31): TABLE-US-00064
TISYNGYTYYIPSLRG.
[0261] Single amino acid sequence of FR3 of the heavy chain of
human monoclonal antibodies F431 and COMB specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:63): TABLE-US-00065
RVTISGDTSKNQFSLRVNSVTAADTAMYYCAR.
[0262] Single amino acid sequence of CDR3 of the heavy chain of
human monoclonal antibodies F431 and COMB specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:32): TABLE-US-00066
HDYSMSSGLTDNWFDP.
[0263] Single amino acid sequence of FR4 of the heavy chain of
human monoclonal antibodies F431 and COMB specific to the P.
aeruginosa MEP antigen (i.e., SEQ ID NO:64): TABLE-US-00067
WGQGTLVTVSS.
Example 2
Materials and Methods
[0264] Binding Assays to P. aeruginosa and purified MEP
[0265] ELISA plates were coated with purified P. aeruginosa MEP at
2 .mu.g/ml in 0.02 M phosphate buffer containing sodium azide
overnight at 4.degree. C. The plates were washed several times to
remove unbound MEP in PBS with 0.05% Tween. The plates were then
incubated overnight at 4.degree. C. with PBS/BSA in order to block
all other non-specific binding sites. Following several washes,
antibodies were added to the plates at various concentrations
ranging from 0.0625 to 2.0 .mu.g/ml. The plates were incubated for
2 hours at room temperature. Bound antibody was detected with an
alkaline phosphatase conjugated goat anti-human IgG antibody
specific for the Fc domain. Assays could similarly be performed
using intact bacteria, as described by Preston et al. Infection and
Immunity 66:4137-4142, 1998.
[0266] Complement Deposition Assays
[0267] ELISA plates were coated with purified P. aeruginosa MEP at
a concentration of 10 .mu.g/ml in 0.02 M phosphate buffer at pH 7,
at room temperature, overnight (e.g., approximately 10 hours).
Antibodies were added at various concentrations and the plates were
incubated for 1 hour at 37.degree. C. Normal human serum was added
as a source of complement. The plates were further incubated for 15
minutes and then washed and incubated with polyclonal rabbit
anti-human C3 antiserum. Rabbit antibodies that bound to C3 were
detected using alkaline phosphatase conjugated goat anti-rabbit
IgG. The OD405 was measured after incubation for 45 minutes at room
temperature.
[0268] Opsonophagocytic Killing Assays
[0269] Opsonophagocytic killing assays have been described
previously. (See Ames et al. Infection and Immunity 49:281-285,
1985.) Briefly, 25 assays are carried out in the presence of 10%
heat-inactivated fetal bovine serum, and fresh human serum is used
as a complement source at a 1:10 dilution. The serum is pre-exposed
to for 30 minutes on ice to P. aeruginosa in order to remove any
pre-existing P. aeruginosa specific antibodies. The assay was
carried out by mixing 100 .mu.l of bacteria at 2.times.10.sup.7
bacteria/ml, 100 .mu.l of different dilutions of the test antibody,
100 .mu.l of purified fresh human polymorphonuclear leukocytes
(PMN) at 2.times.10.sup.7 cells/ml as a source of phagocytic cells,
and 100 .mu.l of absorbed serum as a complement source. Controls
lacked PMNs. The test and control tubes were incubated for 60
minutes at 37.degree. C. with constant agitation. To test for
lysis, aliquots were removed, diluted and cultured in agar plates.
Following overnight incubation, the plates were scored for colony
growth. The percent reduction in the colony forming units (CFU)
relative to that in control assay tubes was calculated as follows:
[ (CFU surviving in the absence of PMNs-CFU surviving in the
presence of PMNs)/CFU surviving in the absence of
PMNs].times.100.
[0270] In vivo Bacterial Challenge Survival Assays:
[0271] Mice were anesthetized using ketamine and xylamine, and then
administered 50 .mu.g of either control or test monoclonal antibody
(F429.gamma.1 and FCOMB.gamma.1) by intranasal instillation at 4
hours prior to challenge. Mice were then challenged with live P.
aeruginosa strain N13 (5.times.10.sup.7 cfu/mouse) by the same
route of administration as antibody. Survival was measured up to
five days after challenge.
Results:
[0272] All the antibodies tested were able to bind to MEP, albeit
with different affinities. At the highest concentration of antibody
tested (2.0 .mu.g/ml), FCOMB.gamma.1 was able to bind MEP to the
greatest degree (FIG. 1). The affinities of the other antibodies at
this concentration were (in decreasing order) F431.gamma.1,
F428.gamma.1, and F429.gamma.1. At the lowest concentration of
antibody tested (0.0625 .mu.g/ml), the F431.gamma.1 showed the
greatest affinity. The affinities of the other antibodies at this
lower concentration were (in decreasing order) FCOMB.gamma.1,
F428.gamma.1, and F429.gamma.1.
[0273] The ability of F429.gamma.1 to induce opsonic killing of
eleven different mucoid and non-mucoid P. aeruginosa strains was
analyzed (FIG. 2). Four mucoid strains (581, 2192, FRD1, and 324)
and seven non-mucoid strains (324 NM, 2344 NM, PA14 NM, FRD1131,
N6, N8, and N13) were used. F429.gamma.1 was used at a
concentration ranging from 4-25 .mu.g per assay. The antibody was
able to induce at least 60% killing (as compared to a control which
lacked any antibody) for each mucoid strain tested. It was
similarly able to induce at least 60% killing in four of the seven
non-mucoid strains tested (324 NM, N6, N8, and N13). In two of the
seven non-mucoid strains (2344 NM and FRD1131), F429.gamma.1 was
able to induce at least 25% killing. The remaining non-mucoid
strain (PA14 NM) was relatively resistant to killing by
F429.gamma.1, with less than 5% killing observed. These results
indicate that the F429.gamma.1 antibody is able to recognize and
induce opsonic killing of mucoid and non-mucoid strains.
[0274] To test the ability of F429.gamma.1 to induce opsonic
killing of natural isolates of P. aeruginosa, four P. aeruginosa
strains were recovered from the blood of bacteremic patients and
the susceptibility to F429.gamma.1-induced opsonic killing was
tested (FIG. 3). F429.gamma.1 was used at concentrations ranging
from 0.01 .mu.g to 10.0 .mu.g. The four isolates used were B312,
JG1, EM1, and 11B1874-2. A concentration dependent effect was
observed for all isolates. At the lowest dose of F429.gamma.1 (0.01
.mu.g), the antibody was effective at inducing at least 20% killing
for all isolates. When used at 1.0 .mu.g, the antibody was able to
induce at least 55% kill in all the isolates, with two of the
isolates demonstrating greater susceptibility to the antibody (B312
and EM1).
[0275] To test the efficacy of the antibodies in vivo, F429.gamma.1
and FCOMB.gamma.1 were administered to murine subjects by
intranasal instillation (50 .mu.g) followed by challenge with live
P. aeruginosa strain N13 (FIG. 4). Survival was monitored for up to
five days after challenge. FIG. 4 shows the survival curve of mice
following challenge. None of the mice administered control
antibody, about 25% of animals administered FCOMB.gamma.1, and 100%
of animals administered F429.gamma.1 survived the challenge with
strain N13. These data show that both F429.gamma.1 and
FCOMB.gamma.1 impart protection to mice challenged with P.
aeruginosa, although F429.gamma.1 was more effective than
FCOMB.gamma.1.
Equivalents
[0276] The foregoing written specification is to be considered to
be sufficient to enable one skilled in the art to practice the
invention. The particular antibodies and peptides disclosed herein
are not to be construed as limiting of the invention as they are
intended merely as illustrative of particular embodiments of the
invention as enabled herein. Therefore, any peptides, antibodies,
and antibody fragments that are functionally equivalent to those
described herein are within the spirit and scope of the claims
appended hereto. Indeed, various modifications of the invention in
addition to those shown and described herein will become apparent
to those skilled in the art from the foregoing description and fall
within the scope of the appended claims.
[0277] All references, patents and patent publications that are
recited in this application are incorporated in their entirety
herein by reference.
Sequence CWU 0
0
SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 64 <210>
SEQ ID NO 1 <211> LENGTH: 369 <212> TYPE: DNA
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 1
cagctgcagc tgcaggagtc gggccccgga ctggtgaagc ctacggagac cctgtccctc
60 acctgcactg tctctggtgg ccccatcacc tatattaatt actactgggg
ctgggtccgc 120 cagcccccag ggaaggggct ggagtggatt gggagtatcc
attatgatgg gagcaccttc 180 tacaacccgt ccctcaagag tcgcgtcacc
atatcaggag acacgtccaa gagcgagttc 240 tctgtgaagc tgagttctgt
gaccgccgcg gacacggccg tctattactg tgcgagaacg 300 tattacgatg
cttcggggag cccttacttt gaccactggg gccagggaac cctggtcacc 360
gtctcctca 369 <210> SEQ ID NO 2 <211> LENGTH: 330
<212> TYPE: DNA <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 2 cagtctgtgt tgacgcagcc gccctcagtg tctgcggccc
caggacagag ggtcaccatc 60 tcctgctctg gaagcagctc caaccttggg
aacaattttg tatcctggta ccagcaactc 120 ccaggagcag ccccccggct
cctcatttat gacaatgata agcgaccctc agggattcct 180 gaccgattct
ctggctccaa gtctggcacg tcagccaccc tgggcatcac cgggctccag 240
actggggacg aggccgatta ttactgcgga acatgggata gcagcctgac tgcttatgtc
300 ttcggaagtg ggaccaaggt caccgtccta 330 <210> SEQ ID NO 3
<211> LENGTH: 330 <212> TYPE: DNA <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 3 cagtctgtgt tgacgcagcc
gccctcagtg tctgcggccc caggacagaa ggtctccatc 60 tcctgctctg
gaagcagctc caacattggg aataattatg tatcctggta ccagcagctc 120
ccaggaacag cccccaatct cctcatttat gacaataata agcgaccctc agggattccg
180 gaccgattct ctggctccaa gtctggcacg tcagccaccc tggacatcac
cggactccag 240 agtggggacg aggccgatta ttactgcgga acatgggata
gcagcctgag tacttgggtg 300 ttcggcggag ggaccaaact gaccgtccta 330
<210> SEQ ID NO 4 <211> LENGTH: 378 <212> TYPE:
DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 4
cagctgcacc tgcaggagtc gggcccagga ctagtgaagc cttcggagac cctgtccctc
60 acgtgcactg tctctggtgg ccccatcacc agtaataatt actactgggg
ctggatccgc 120 cagcccccag ggaaggggct ggagtggatt gggactatct
cttataatgg gtacacctac 180 tacatcccgt ccctcagggg tcgagtcacc
atatccggag acacgtccaa gaaccagttc 240 tccctgaggg tgaactctgt
gaccgccgca gacacggcta tgtattactg tgcgagacat 300 gactatagca
tgtcgtccgg acttactgac aactggttcg acccctgggg ccagggaacc 360
ctggtcaccg tctcctca 378 <210> SEQ ID NO 5 <211> LENGTH:
123 <212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 5 Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu
Val Lys Pro Thr Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser
Gly Gly Pro Ile Thr Tyr Ile 20 25 30 Asn Tyr Tyr Trp Gly Trp Val
Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Ser Ile
His Tyr Asp Gly Ser Thr Phe Tyr Asn Pro Ser 50 55 60 Leu Lys Ser
Arg Val Thr Ile Ser Gly Asp Thr Ser Lys Ser Glu Phe 65 70 75 80 Ser
Val Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90
95 Cys Ala Arg Thr Tyr Tyr Asp Ala Ser Gly Ser Pro Tyr Phe Asp His
100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120
<210> SEQ ID NO 6 <211> LENGTH: 109 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 6 Gln
Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10
15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Leu Gly Asn Asn
20 25 30 Phe Val Ser Trp Tyr Gln Gln Leu Pro Gly Ala Ala Pro Arg
Leu Leu 35 40 45 Ile Tyr Asp Asn Asp Lys Arg Pro Ser Gly Ile Pro
Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu
Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr
Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Thr Ala Tyr Val Phe Gly
Ser Gly Thr Lys Val Thr Val 100 105 <210> SEQ ID NO 7
<211> LENGTH: 110 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 7 Gln Ser Val Leu Thr Gln Pro
Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Ser Ile Ser
Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser
Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Asn Leu Leu 35 40 45 Ile
Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55
60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Asp Ile Thr Gly Leu Gln
65 70 75 80 Ser Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser
Ser Leu 85 90 95 Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr
Val Leu 100 105 110 <210> SEQ ID NO 8 <211> LENGTH: 126
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 8 Gln Leu His Leu Gln Glu Ser Gly Pro Gly Leu
Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser
Gly Gly Pro Ile Thr Ser Asn 20 25 30 Asn Tyr Tyr Trp Gly Trp Ile
Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Thr Ile
Ser Tyr Asn Gly Tyr Thr Tyr Tyr Ile Pro Ser 50 55 60 Leu Arg Gly
Arg Val Thr Ile Ser Gly Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser
Leu Arg Val Asn Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr 85 90
95 Cys Ala Arg His Asp Tyr Ser Met Ser Ser Gly Leu Thr Asp Asn Trp
100 105 110 Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125 <210> SEQ ID NO 9 <211> LENGTH: 21
<212> TYPE: DNA <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 9 tatattaatt actactgggg c 21 <210> SEQ
ID NO 10 <211> LENGTH: 48 <212> TYPE: DNA <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 10 agtatccatt
atgatgggag caccttctac aacccgtccc tcaagagt 48 <210> SEQ ID NO
11 <211> LENGTH: 39 <212> TYPE: DNA <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 11 acgtattacg
atgcttcggg gagcccttac tttgaccac 39 <210> SEQ ID NO 12
<211> LENGTH: 39 <212> TYPE: DNA <213> ORGANISM:
Homo sapiens
<400> SEQUENCE: 12 tctggaagca gctccaacct tgggaacaat tttgtatcc
39 <210> SEQ ID NO 13 <211> LENGTH: 21 <212>
TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE:
13 gacaatgata agcgaccctc a 21 <210> SEQ ID NO 14 <211>
LENGTH: 33 <212> TYPE: DNA <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 14 ggaacatggg atagcagcct gactgcttat gtc 33
<210> SEQ ID NO 15 <211> LENGTH: 39 <212> TYPE:
DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 15
tctggaagca gctccaacat tgggaataat tatgtatcc 39 <210> SEQ ID NO
16 <211> LENGTH: 21 <212> TYPE: DNA <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 16 gacaataata
agcgaccctc a 21 <210> SEQ ID NO 17 <211> LENGTH: 33
<212> TYPE: DNA <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 17 ggaacatggg atagcagcct gagtacttgg gtg 33
<210> SEQ ID NO 18 <211> LENGTH: 21 <212> TYPE:
DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 18
agtaataatt actactgggg c 21 <210> SEQ ID NO 19 <211>
LENGTH: 48 <212> TYPE: DNA <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 19 actatctctt ataatgggta cacctactac
atcccgtccc tcaggggt 48 <210> SEQ ID NO 20 <211> LENGTH:
48 <212> TYPE: DNA <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 20 catgactata gcatgtcgtc cggacttact
gacaactggt tcgacccc 48 <210> SEQ ID NO 21 <211> LENGTH:
7 <212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 21 Tyr Ile Asn Tyr Tyr Trp Gly 1 5
<210> SEQ ID NO 22 <211> LENGTH: 16 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 22 Ser
Ile His Tyr Asp Gly Ser Thr Phe Tyr Asn Pro Ser Leu Lys Ser 1 5 10
15 <210> SEQ ID NO 23 <211> LENGTH: 13 <212>
TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:
23 Thr Tyr Tyr Asp Ala Ser Gly Ser Pro Tyr Phe Asp His 1 5 10
<210> SEQ ID NO 24 <211> LENGTH: 13 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 24 Ser
Gly Ser Ser Ser Asn Leu Gly Asn Asn Phe Val Ser 1 5 10 <210>
SEQ ID NO 25 <211> LENGTH: 7 <212> TYPE: PRT
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 25 Asp Asn
Asp Lys Arg Pro Ser 1 5 <210> SEQ ID NO 26 <211>
LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 26 Gly Thr Trp Asp Ser Ser Leu Thr Ala Tyr
Val 1 5 10 <210> SEQ ID NO 27 <211> LENGTH: 13
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 27 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
Tyr Val Ser 1 5 10 <210> SEQ ID NO 28 <211> LENGTH: 7
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 28 Asp Asn Asn Lys Arg Pro Ser 1 5
<210> SEQ ID NO 29 <211> LENGTH: 11 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 29 Gly
Thr Trp Asp Ser Ser Leu Ser Thr Trp Val 1 5 10 <210> SEQ ID
NO 30 <211> LENGTH: 7 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 30 Ser Asn Asn Tyr Tyr
Trp Gly 1 5 <210> SEQ ID NO 31 <211> LENGTH: 16
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 31 Thr Ile Ser Tyr Asn Gly Tyr Thr Tyr Tyr
Ile Pro Ser Leu Arg Gly 1 5 10 15 <210> SEQ ID NO 32
<211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 32 His Asp Tyr Ser Met Ser Ser
Gly Leu Thr Asp Asn Trp Phe Asp Pro 1 5 10 15 <210> SEQ ID NO
33 <211> LENGTH: 90 <212> TYPE: DNA <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 33 cagctgcagc
tgcaggagtc gggccccgga ctggtgaagc ctacggagac cctgtccctc 60
acctgcactg tctctggtgg ccccatcacc 90 <210> SEQ ID NO 34
<211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 34 tgggtccgcc agcccccagg
gaaggggctg gagtggattg gg 42 <210> SEQ ID NO 35 <211>
LENGTH: 96 <212> TYPE: DNA <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 35 cgcgtcacca tatcaggaga cacgtccaag
agcgagttct ctgtgaagct gagttctgtg 60 accgccgcgg acacggccgt
ctattactgt gcgaga 96
<210> SEQ ID NO 36 <211> LENGTH: 33 <212> TYPE:
DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 36
tggggccagg gaaccctggt caccgtctcc tca 33 <210> SEQ ID NO 37
<211> LENGTH: 66 <212> TYPE: DNA <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 37 cagtctgtgt tgacgcagcc
gccctcagtg tctgcggccc caggacagag ggtcaccatc 60 tcctgc 66
<210> SEQ ID NO 38 <211> LENGTH: 45 <212> TYPE:
DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 38
tggtaccagc aactcccagg agcagccccc cggctcctca tttat 45 <210>
SEQ ID NO 39 <211> LENGTH: 96 <212> TYPE: DNA
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 39
gggattcctg accgattctc tggctccaag tctggcacgt cagccaccct gggcatcacc
60 gggctccaga ctggggacga ggccgattat tactgc 96 <210> SEQ ID NO
40 <211> LENGTH: 30 <212> TYPE: DNA <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 40 ttcggaagtg
ggaccaaggt caccgtccta 30 <210> SEQ ID NO 41 <211>
LENGTH: 66 <212> TYPE: DNA <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 41 cagtctgtgt tgacgcagcc gccctcagtg
tctgcggccc caggacagaa ggtctccatc 60 tcctgc 66 <210> SEQ ID NO
42 <211> LENGTH: 45 <212> TYPE: DNA <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 42 tggtaccagc
agctcccagg aacagccccc aatctcctca tttat 45 <210> SEQ ID NO 43
<211> LENGTH: 96 <212> TYPE: DNA <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 43 gggattccgg accgattctc
tggctccaag tctggcacgt cagccaccct ggacatcacc 60 ggactccaga
gtggggacga ggccgattat tactgc 96 <210> SEQ ID NO 44
<211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 44 ttcggcggag ggaccaaact
gaccgtccta 30 <210> SEQ ID NO 45 <211> LENGTH: 90
<212> TYPE: DNA <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 45 cagctgcacc tgcaggagtc gggcccagga
ctagtgaagc cttcggagac cctgtccctc 60 acgtgcactg tctctggtgg
ccccatcacc 90 <210> SEQ ID NO 46 <211> LENGTH: 42
<212> TYPE: DNA <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 46 tggatccgcc agcccccagg gaaggggctg
gagtggattg gg 42 <210> SEQ ID NO 47 <211> LENGTH: 95
<212> TYPE: DNA <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 47 cgagtcacca tatccggaga cacgtccaag
aaccagttct ccctgagggt gaactctgtg 60 accgccgcag acacggctat
gtattactgt gcgag 95 <210> SEQ ID NO 48 <211> LENGTH: 33
<212> TYPE: DNA <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 48 tggggccagg gaaccctggt caccgtctcc tca 33
<210> SEQ ID NO 49 <211> LENGTH: 30 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 49 Gln
Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Thr Glu 1 5 10
15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Pro Ile Thr 20 25 30
<210> SEQ ID NO 50 <211> LENGTH: 14 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 50 Trp
Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly 1 5 10
<210> SEQ ID NO 51 <211> LENGTH: 32 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 51 Arg
Val Thr Ile Ser Gly Asp Thr Ser Lys Ser Glu Phe Ser Val Lys 1 5 10
15 Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30 <210> SEQ ID NO 52 <211> LENGTH: 11
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 52 Trp Gly Gln Gly Thr Leu Val Thr Val Ser
Ser 1 5 10 <210> SEQ ID NO 53 <211> LENGTH: 22
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 53 Gln Ser Val Leu Thr Gln Pro Pro Ser Val
Ser Ala Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys 20
<210> SEQ ID NO 54 <211> LENGTH: 15 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 54 Trp
Tyr Gln Gln Leu Pro Gly Ala Ala Pro Arg Leu Leu Ile Tyr 1 5 10 15
<210> SEQ ID NO 55 <211> LENGTH: 32 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 55 Gly
Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr 1 5 10
15 Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys
20 25 30 <210> SEQ ID NO 56 <211> LENGTH: 9 <212>
TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:
56 Phe Gly Ser Gly Thr Lys Val Thr Val 1 5 <210> SEQ ID NO 57
<211> LENGTH: 22 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 57 Gln Ser Val Leu Thr Gln Pro
Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15 Lys Val Ser Ile Ser Cys 20 <210> SEQ ID NO 58
<211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 58 Trp Tyr Gln Gln Leu Pro Gly
Thr Ala Pro Asn Leu Leu Ile Tyr 1 5 10 15 <210> SEQ ID NO 59
<211> LENGTH: 32 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 59 Gly Ile Pro Asp Arg Phe Ser
Gly Ser Lys Ser Gly Thr Ser Ala Thr 1 5 10 15 Leu Asp Ile Thr Gly
Leu Gln Ser Gly Asp Glu Ala Asp Tyr Tyr Cys 20 25 30 <210>
SEQ ID NO 60 <211> LENGTH: 10 <212> TYPE: PRT
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 60 Phe Gly
Gly Gly Thr Lys Leu Thr Val Leu 1 5 10 <210> SEQ ID NO 61
<211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 61 Gln Leu His Leu Gln Glu Ser
Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr
Cys Thr Val Ser Gly Gly Pro Ile Thr 20 25 30 <210> SEQ ID NO
62 <211> LENGTH: 14 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 62 Trp Ile Arg Gln Pro
Pro Gly Lys Gly Leu Glu Trp Ile Gly 1 5 10 <210> SEQ ID NO 63
<211> LENGTH: 32 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 63 Arg Val Thr Ile Ser Gly Asp
Thr Ser Lys Asn Gln Phe Ser Leu Arg 1 5 10 15 Val Asn Ser Val Thr
Ala Ala Asp Thr Ala Met Tyr Tyr Cys Ala Arg 20 25 30 <210>
SEQ ID NO 64 <211> LENGTH: 11 <212> TYPE: PRT
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 64 Trp Gly
Gln Gly Thr Leu Val Thr Val Ser Ser 1 5 10
* * * * *